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Glycosphingolipids, due to their tendency to form laterally separated liquid-ordered
phases, possess a high potential for the creation of order in biological membranes. The
formation of glycosphingolipid-rich membrane domains within the membrane has
profound consequences on the membrane organization at different levels, and on the
conformational and biological properties of membrane-associated proteins and
multimolecular protein complexes (1).
Glycosphingolipids modulate several signal transduction processes controlling cell
proliferation, survival, differentiation, and transformation. Since alterations in the
expression of carbohydrate epitopes associated with glycosphingolipids are frequent in
tumors, it has been hypothesized that glycosphingolipids could play important roles in
modulating some of the properties of tumor cells. In fact, some tumors are characterized
by the ability to manipulate sialylation processes determining the formation of antigenic
determinants resulting from an “aberrant glycosylation” and affecting cell homeostasis,
altering the normal signaling pathways (2). Thus, an ever-increasing interest to this
regard is being devoted to gangliosides, sialic acid-containing glycolipids, and to the
enzymes affecting sialylation. Both sialyltransferases and sialidases seem to be involved
in the phenomenon of aberrant sialylation in tumor cells.
The genetic (stable overexpression of sialyltransferase I - SAT-I or GM3 synthase) or
pharmacological (selective pressure by N-(4-hydroxyphenyl)retinamide) manipulation
of A2780 human ovarian carcinoma cells allowed us to obtain monoclonal cells
characterized by higher GM3 synthase activity respect to wild type cells (3-5). High
GM3 synthase expression resulted in 1) elevated ganglioside levels, 2) reduced in vitro
cell motility and increased adhesion to fibronectin, 3) enhanced expression of the
membrane adaptor protein caveolin-1, an integral membrane protein playing multiple
roles as negative regulator in the progression of several types of human tumors (6,7).
The correlation between high ganglioside levels and decreased motility/increased
adhesion were confirmed through administration of exogenous gangliosides which was
not only able to strongly reduce in vitro cell motility, but also to significantly increase
cell adhesive ability to fibronectin in wild type cells, low GM3 synthase expressing
A2780 cells. Furthermore, in high GM3 synthase expressing clones, such as
A2780/SAT-I cells, ganglioside depletion by treatment with the glucosylceramide
synthase inhibitor D-PDMP was able to strongly reduce adhesion and to increase cell
motility.
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The α5β1 integrin, which mediates cell adhesion, is the most expressed integrin
heterodimers in A2780 cells. Since fibronectin is the preferential ligand of integrin α5β1,
it has been hypothesized that this integrin heterodimer might be involved in the
regulation of adhesion and motility in human ovarian carcinoma cells. On the other
hand, A2780/SAT-I cells also showed an increased adhesion to laminin and vitronectin
suggesting a possible role of their respective integrin receptors in the regulation of
GM3-mediated adhesion.
The role of a glycosphingolipid/caveolin-1 signaling complex in the negative regulation
of A2780 cells motility has been reported, showing that high levels of caveolin-1 and
high levels of gangliosides are necessary, but not sufficient, to down-regulate tumor cell
motility (5). In GM3 synthase expressing cells, caveolin-1 and gangliosides were highly
enriched in detergent-resistant membrane fractions (DRM) prepared in the presence of
Triton X-100. D-PDMP treatment determined changes in the lipid distribution of
several lipids in sucrose gradient fractions, and also altered protein distribution
determining a shift of both caveolin-1 and c-Src, also involved in the previously
mentioned complex signaling pathway, from the DRM fraction to intermediate fraction.
Integrins, particularly α5 and β1 integrin subunits, following ganglioside depletion
move from the high density fraction to DRM and intermediate fractions. D-PDMP
treatment also affected protein association with caveolin-1, determining an increased
association of this protein, a potential molecular organizer, with integrin subunits α5
and β1 without affecting the total level of proteins.
The in vitro adhesion of A2780/SAT-I cells was markedly higher in caveolin-1 silenced
cells compared with scramble sequence transfected cells, suggesting a leading role of
caveolin-1 in the regulation of the cell adhesion signal in this cell model. On the other
hand, treatment of A2780 cells with exogenous gangliosides only slightly increased the
expression of caveolin-1; while it markedly increased the phosphorylation of caveolin-1
at tyrosine 14. Conversely, ganglioside depletion in high GM3 synthase-expressing
clones by D-PDMP treatment markedly reduced caveolin-1 phosphorylation. These data
suggest that phosphorylation of caveolin-1, rather than caveolin-1 total level, is
controlled by gangliosides and is crucial in the control of tumor cell adhesion.
These data suggest a novel role of gangliosides in regulating tumor cell adhesion and
motility, by affecting the organization of a signaling complex organized by caveolin-1,
and imply that GM3 synthase is a key target for the regulation of cell motility and
adhesion in human ovarian carcinoma.
INTRODUCTION
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Glycosphingolipids
Overview
All eukaryotic cells are surrounded by a membrane composed of a lipid bilayer, whose
chemical nature and essential role in cell permeability were first proposed around a
hundred years ago. Today it is known that there are three major classes of lipids in
eukaryotic cell membranes, namely glycerolipids, sphingolipids, and sterols, whose
biochemical and biophysical properties vary considerably and impact upon their
function (8). Glycerophospholipids are by far the main lipids of eukaryotic cell
membranes. Sphingolipids are minor cell components, mainly residing in the external
layer of the plasma membrane (9) with the hydrophilic headgroup protruding toward the
extracellular environment. They constitute a family of amphipathic lipids found in
essentially all animals, plants and fungi, some prokaryotic organisms and viruses, and
involved in numerous and important biological functions (10). Ceramide is the simplest
sphingolipid: it is formed by a long chain sphingoid base linked to a fatty acid through
an amide bound. In mammalian tissues the most common sphingoid base is sphingosine
(2S,3R-d-erythro-2-amino-1,3-octadec-4E-ene-diol, also called trans-4-sphingenine), a
18 carbon atoms primary amine with a double bond in position 4,5 and two hydroxyl
groups in position 1 and 3. Homologous lipids with a different length of the carbon
chain or with a saturated chain, sphinganine or 4-hydroxy-sphinganine, are present in
cells in minor amount (11). Ceramide is the backbone of all complex sphingolipids
which are characterized by the presence of a charged group linked to the hydroxylated
group in position 1 of the sphingoid base (12). The polar group, that defines the specific
sphingolipid class, is a phosphate group in ceramide-1-phosphate, phosphorylcholine in
sphingomyelin, monosaccharides in cerebrosides, one or more sugar residues linked
with a β-glycosidic bond in complex glycosphingolipids. Glycosphingolipids are the
most structurally diverse class of complex sphingolipids, and are normally classified as
acidic, neutral or basic (8,13). They are ubiquitous components of mammal cell
membranes, but are particularly abundant in the nervous system.
A particular class of acidic glycosphingolipids, named gangliosides, was discovered in
1936 by Ernest Klenk in the central nervous system. Gangliosides are sialic acid-
containing glycosphingolipids, and have been considered to be involved in the
development, differentiation, and function of nervous systems in vertebrates (14). In
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cells, gangliosides are primarily localized in the extracellular leaflet of the plasma
membrane where they are not homogenously distributed (15). On the cell surface,
gangliosides are involved in cell-cell recognition, adhesion and signal transduction
within specific cell surface microdomains, named caveolae (16), lipid rafts (17), or
glycosphingolipid-enriched microdomains (18) with other membrane components such
as sphingomyelin and cholesterol. Evidence is accumulating that gangliosides are
colocalized in the microdomain structures with signaling molecules and adhesion
molecules which suggests their involvement in the modulation of process such as cell
proliferation, survival, adhesion, and neuronal differentiation. In addition to cell plasma
membranes, gangliosides have been shown to be present on nuclear membranes, and
they have recently been proposed to play important roles in modulating intracellular and
intranuclear calcium homeostasis and the ensuing cellular functions (19). Many
different experimental approaches, leading eventually to alterations in the organization
of the plasma membrane due to quali- or quantitative changes in glycosphingolipid
content or pattern, have been proven to be very effective in modulating the above
mentioned cell functions. On the other hand, catabolic fragments derived from plasma
membrane sphingolipids (ceramide, sphingosine, and sphingosine-1-phosphate)
ermerged as a class of lipid mediators capable of modulating cell proliferation,
differentiation, motility or apoptotic cell death.
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Figure 1. Structure of GM1, GM2 and GM3 ganglioside
Glycosphingolipids biosynthesis, trafficking and degradation
The biochemical pathways of glycosphingolipids metabolism and the intracellular sites
of synthesis and degradation, in the endoplasmic reticulum/Gogli apparatus and
lysosomes, respectively, have been characterized extensively over the past couple of
decades (20,21). The biosynthesis of glycosphingolipids starts at the cytosolic leaflet of
membranes of the endoplasmic reticulum (ER) where ceramide is synthesized by a
sequence of three enzyme-catalysed reactions from L-Serine and two molecules of
coenzyme A (CoA) activated fatty acid, namely palmitoyl-CoA (22). After its synthesis,
ceramide equilibrates to the luminal side of the ER where it can be transformed into
galactosylceramide (GalCer) by ceramide galactosyltransferase (23). GalCer after its
synthesis traffics through the Golgi apparatus where it may be sulfated (24) or
glycosylated (22). Ceramide is also transported from the ER to the cytosolic side of the
cis-Golgi apparatus membrane by a CERT-independent mechanism (25,26). Here a
transmembrane glycosyl transferase, glucosylceramide synthase, catalyses the
glycosylation of the primary hydroxyl group in ceramide using UDP-glucose as a donor
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glycoside. The glucosylceramide synthase has its catalytic site facing the cytosol where
newly produced glucosylceramide (GlcCer) can be recognized by lipid transport protein
FAPP2 which mediates the non-vescicular transport of glucosylceramide to distal Golgi
compartments (27,28). GlcCer then flips into the Golgi lumen, where the addition of the
next sugar residue leads to the formation of lactosylceramide (LacCer). GalCer and
GlcCer are precursors of the hundreds of known glycosphingolipids, which are formed
by the sequential transfer of sugars by galactosyltransferases, sialyltransferases,
GalNAc transferases and GalCer sulfotransferases, all of which are located in the Golgi
apparatus (29). The final orientation of glycosphingolipids during biosynthesis is
consistent with their nearly exclusive appearance on the outer leaflet of the plasma
membrane. Although ceramide resides on intracellular organelles such as mitochondria,
glycosphingolipids beyond GlcCer are not known to exist on membranes facing the
cytoplasm (30,31). The biosynthesis of glycosphingolipids in the brain provides an
example of how competing biosynthetic pathways can lead to glycan structural diversity
(32). In the brain, stepwise biosynthesis of GalCer and sulfatide occurs in
oligodendrocytes, the cells that elaborate myelin. During oligodendrocyte differentiation,
sulfatide is first detected at the stage of immature oligodendrocytes and is upregulated
before cells wrap myelin around axons, suggesting that sulfatide not only fulfills a role
as a structural component of myelin (33). Gangliosides, in contrast, are synthesized by
all cells, with concentration of the different forms varying according to cell type.
During development the expression patterns of glycosphingolipids shifts from simple
gangliosides, such as GM3 and GD3, to complex gangliosides, such as GM1, GD1a,
GD1b, and GT1b. This shift is regulated primarily by the differential expression and
intracellular distribution of the enzymes required for the biosynthesis of the
glycosphingolipids (34). In some cases, multiple glycosyltransferases compete for the
same glycosphingolipid precursor (35). For example, two enzymes accept LacCer as a
substrate: sialyltransferase I that forms ganglioside GM3 and GalNAc-transferase that
forms glycolipid GA2 even though for different reasons, including different enzyme
kinetic constants and enzyme and substrates cellular localization, much more GM3 is
formed than GA2 (21,36,37). Another example, the ganglioside GM3 may be acted on
by N-acetylgalactosaminyltransferase, thereby forming GM2, the simplest of the “a-
series” gangliosides, or by sialyltransferase II, thus forming GD3, the simplest of the
“b-series” gangliosides (38,39). Since sialyltransferases cannot directly convert a-series
gangliosides to their corresponding b-series gangliosides, each branch is considered a
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committed pathway. Due to this branch exclusivity, the relative expression level of the
final glycosphingolipids products is determined by the competition of two enzymes at a
key branch point. The transfer of N-acetylgalactosamine to a-, b-, and c-series
gangliosides, transforming GM3 into GM2, GD3 into GD2, or GT3 into GT2, is
catalysed by the same N-acetylgalactosaminyltransferase. Likewise, the transfer of
galactose to GM2 to form GM1, to GD2 to from GD1b, or to GT2 to form GT1c is
accomplished by a single galactosyltransferase (40). An additional level of regulation
may occur via stable association of different glycosphingolipid glycosyltransferases into
functional “multiglycosyltransferase” complexes. The enzymes involved are thought to
act concertedly on the growing glycosphingolipid without releasing intermediate
structures, ensuring progression to the preferred end product (41).
The breakdown of glycosphingolipids is a stepwise process that occurs predominantly
in endosomes and lysosomes. Glycosphingolipid-rich membrane parts are internalized
and fuse with early endosomes. Here, glycosphingolipids destined for degradation are
sorted through formation of multivescicular bodies which reach the lysosomes. After
the fusion with the primary lysosomes, glycosphingolipid become exposed to lysosomal
hydrolases and, in vivo, they are eventually broken down to their individual components,
which are then available for reuse (42,43). Metabolism of endocytosed
glycosphingolipids is not restricted to the lysosomes. In fact, a limited amount of
GlcCer derived from the degradation of complex glycosphingolipids may escape further
lysosomal degradation and reenter the glycosphingolipid pathway (44). In addition,
direct metabolic remodeling of glycosphingolipids at the plasma membrane may result
in local formation of simpler glycosphingolipids from complex ones (45).
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Figure 2. Biosynthetic pathway of ganglio-series derived GSLs.
Glycosphingolipids are abbreviated according to the recommendations of
the International Union of Pure and Applied Chemistry - International
Union of Biochemistry Joint Commision on Biochemical Glycolipids
(Jennermann, R. et al., 2013).
Biological functions of glycosphingolipids
Glycosphingolipids are essential for the survival, proliferation, and differentiation of
eukaryotic cells within complex multicellular systems. Several studies involving the
analysis of genetically engineered mice deficient in gangliosides synthases have
revealed the vital importance of glycosphingolipids in the life of the cells that are
dealing with a multifaceted extracellular reality. Glycolipid-deficient cells, such as the
CM-95 mutant melanoma cell line, lacking glucosylceramide synthase activity (46), and
embryonic stem cells from glucosylceramide synthase knockout mice (47) are able to
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survive, grow, and undergo through in vitro differentiation. However, glucosylceramide
synthase knockout mice are embryonic lethal, and showed no cellular differentiation
beyond the primitive germ layers (48). Mice lacking all ganglioside expression resulting
from knockout of both GalNAcT and SAT-I genes suffer severe lethality. These
ganglioside-deficient mice reveal enhanced cell apoptosis, axonal degeneration and
perturbed axon-glia interactions (49). It still remains to be cleared whether those
phenotypes result from functional deficiency of the particular ganglioside product or
from an acquired consequence of the accumulation of substrate precursors.
As mentioned in the previous sections, glycosphingolipids are not randomly distributed
along the membrane surface, but they are highly segregated together with cholesterol in
lipid domains with specialized signaling functions (50). The glycosphingolipids are
usually highly asymmetrically enriched in the external leaflet of the plasma membranes,
with the oligosaccharide chain protruded toward the extracellular space, where the sugar
residues can engage cis and trans interactions with a wide variety of cell surface and
extracellular molecules (51). These interactions are influenced by the local
concentration of glycosphingolipids in the plasma membrane. In the case of trans
interactions, it has been shown that recognition of lipid-bound oligosaccharides by
soluble ligands (for example antibodies or toxins) or by complementary carbohydrates
and by carbohydrate binding proteins (such as selectins or lectins) belonging to the
interfacing membrane of adjacent cells is strongly affected by their degree of dispersion
(or segregation) (52). On the other hand, direct lateral interactions (cis interactions) with
plasma membrane proteins or short range alterations of the lipid microenvironment of
plasma membrane proteins, are strongly favored within a sphingolipid-enriched
membrane domain (53). There is a large body of data showing roles for
glycosphingolipids as antigens, as mediators of cell adhesion, through trans interactions,
and as modulators of signal transduction and the list of functions of glycosphingolipids
is extensive. Administration of exogenous gangliosides dissolved in the culture medium
is a widely used experimental model for the study of these functions in intact cells or in
membrane preparations. The binding, uptake and metabolic fate of exogenous
gangliosides under different experimental conditions have been well characterized
(44,54). The addition of exogenous gangliosides resulted in the modulation of the
biological activity of tyrosine kinase receptors, protein kinases and phosphatases, ion
channels and pumps, and in cultured neurons and neurotumoral cell lines, it exerted
neuritogenic, neurotrophic, and neuroprotective effects (34,55,56). Evidence of the role
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of glycosphingolipids as receptors was found studying the internalization of bacterial
toxins. For example, GM1 acts as a receptor for cholera toxin B subunit (57), whereas
Gb3 acts as a receptor for Shiga toxin and verotoxin (58,59). Also two of the surface
proteins of the influenza virus are specifically aimed against the terminal Neu5Ac group
on the glycosphingolipids and glycoproteins of the human host (60).
Many pieces of evidence indicated that sphingolipid biosynthesis is necessary for the
differentiation and function of neurons in culture. Pharmacological inhibition of
glycosphingolipid biosynthesis by synthetic inhibitors of glucosylceramide synthase
(such as D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, D-PDMP) (61),
or by inhibitors of sphinganine N-acyltransferase (the enzyme that catalyses the
synthesis of the biosynthetic precursor of ceramide) (62), reduced axonal elongation and
branching in cultured hippocampal and neocortical neurons (63,64). Conversely, up-
regulation of glycosphingolipid biosynthesis by L-PDMP stimulated neurite outgrowth
in cultured cortical neurons (64). In the same cellular model, D-PDMP and L-PDMP
also exerted opposite effects on the formation of functional synapses and on synaptic
activity (65).
The role of gangliosides in the maintenance of neuronal structure and function can be at
least in part explained by their ability to laterally interact with specific proteins at the
level of the plasma membrane and to modulate their activity. Possible interactions with
functional significance between gangliosides and plasma membrane proteins have been
intensively studied in the past (66-68). Glycosphingolipids are known to interact with
growth factor receptors, to modulate cell growth, and in many cases to inhibit receptor-
associated tyrosine kinases. Well studied examples of these interactions are represented
by epidermal growth factor receptor (EGFR), whose tyrosine phosphorilation and
dimerization are inhibited by GM3, but uninfluenced by GM1 (69), and by insulin
receptor, inhibited by GM3 but not GD1a (70). On the other hand, there is evidence
suggesting that overall lipid raft dynamics, as determined by their peculiar composition,
might be rather responsible for the functional modulation of raft-associated signaling
proteins (17,71,72).
Glycosphingolipids and cancer
Glycosphingolipids play important roles in modulating several properties of tumor cells.
Most tumor cells show altered glycosphingolipid patterns on their surface as well as
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abnormal sphingolipid signaling and increased glycosphingolipid biosynthesis, which
together play a major role in tumor growth, angiogenesis, and metastasis (73,74). For
example, the human sialidase Neu3, which is found on the plasma membrane in
caveolae-containing microdomains and cleaves terminal Neu5Ac residues from
glycosphingolipids, is overexpressed in many types of cancer and plays an important
role in tumor growth and survival (75). Malignant transformation is also associated with
abnormal glycosilation, resulting in the synthesis and expression of altered carbohydrate
determinants, including those on glycosphingolipids. A correlation between the
expression of some of these carbohydrate determinants and tumor patient survival rates
has been observed, and elevated serum ganglioside levels have been reported in patients
(74). On the other hand, in tumor cell lines, the tumorigenic potential correlates with the
cellular levels of gangliosides (76,77), and the ability to form experimental tumors can
be affected by the artificial manipulation of cellular gangliosides levels (78). The
contribution of transformation-associated changes in glycosphingolipids composition to
the tumor phenotype is very complex and likely implies heterogeneous molecular
mechanisms. However, at least two well-established paradigms support this role: 1)
gangliosides have been described as modulators of growth factor receptor function-
associated tyrosine kinase activities and cellular compartmentalization. A well-studied
example is represented by the interaction between GM3 ganglioside and the EGFR.
GM3 negatively regulates ligand-stimulated autophosphorylation and dimerization of
EGFR (79-82), and cross-talk of EGFR with integrin receptors (83) and PKCα (84),
inhibiting EGFR-dependent cell proliferation and survival in neoplastic cells. 2) GM3
and/or GM2 inhibit integrin-dependent tumor cell motility via the formation of a
ganglioside/tetraspanin/integrin receptor complex (the “glycosynapse”) that is
responsible for the negative regulation of c-Src (85) and Met (86,87) tyrosine kinase
activity. Indeed, altered GM3 ganglioside expression plays a multiple role in the control
of tumor cell motility, invasiveness, and survival. GM3 is highly expressed in non-
invasive compared with invasive bladder tumors and derived cell lines (88,89), and the
overexpression of GM3 synthase reduced cell proliferation, motility, and invasion in
mouse bladder carcinoma cells (78). In colorectal (90) and bladder (89) cancer cells,
GM3-mediated inhibition of integrin-dependent cell motility required the expression of
hydrophobic membrane adapter proteins belonging to the tetraspan membrane protein
superfamily (tetraspanins). In bladder cancer cells characterized by high GM3 levels
and by the expression of tetraspanin CD9, a CD9/α3 integrin complex was stabilized by
Introduction
17
GM3-mediated interactions, and the Src C-terminal kinase Csk was recruited to this
complex, with consequent inhibition of c-Src and reduced cell motility (85). On the
other hand, tetraspanin CD82 is essential for the ganglioside-mediated cross-talk of
EGFR with other signaling pathways (84). Thus, a crucial aspect in the control of
receptor function by GSL is represented by their ability to influence the formation of
multimolecular complexes that usually require the presence of hydrophobic membrane
proteins as scaffold or molecular organizers.
Glycosphingolipids are also involved in drug resistance. The effectiveness of many
chemotherapy agents and radiotherapies in treating cancers has been found to rely on
their ability to increase levels of ceramide in tumor cells so as to activate ceramide-
mediated apoptosis. Many tumors have increased expression and activity of
glucosylceramide synthase. Drug resistant cancer cell lines show up to threefold higher
levels of glucosylceramide. Many tumors also achieve drug resistance by actively
pumping out the drugs through the family of ABC transporter proteins. Overexpression
of the most common of these efflux pumps, P-glycoprotein, coincides with abnormally
high glucosylceramide synthase activity in multidrug-resistant breast cancer, leukemia,
melanoma, and colon cancer. P-glycoprotein is a plasma membrane anchored protein
that is situated in GSL-containing membrane microdomains. Through the consumption
of ATP it is capable of transporting a wide range of noncharged amphiphilic molecules,
including glucosylceramide, from the cytosol to the outer plasma membrane.
Overexpression of the P-glycoprotien efflux pump is actually one of the most consistent
hallmarks of drug resistance (91,92).
Caveolin-1
Caveolin-1 structure, localization and function
Caveolins (93,94) are a family of 21- to 24-kDa integral membrane proteins originally
described as the main structural component of caveolae, omega-shaped invaginations of
the plasma membrane that form a subdomain of cholesterol- and sphingolipid-rich lipid
rafts and that are morphologically distinct from the triskelion structure of clathrin-
coated pits (16,95). Caveolae are decorated by a striated coat that is recognized by
antibodies directed against caveolin-1. Caveolin-1 is a key structural component of
caveolae and its expression is essential for caveolae biogenesis (93). Currently, three
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caveolin genes are known to exist. While caveolin-3 is found mainly in skeletal muscle
fibers and cardiac miocytes (96), caveolin-1 and caveolin-2 are co-expressed in most
cells and share many physical properties, although the latter seems to lack full
functional capacity to form caveolae (97). Cav1 is a 178 amino acid protein that was
first identified as a substrate of v-Src kinase in Rous sarcoma virus-transformed chick
fibroblasts (93). In vivo, two isoforms of caveolin-1 are known to exist: α-caveolin that
contains residues 1-178 and β-caveolin that contains residues 32-178. Therefore, only
α-caveolin is able to become tyrosine phosphorylated upon Src transformation (98).
More recently, other tyrosine kinases such as c-Abl and Fyn have been shown to
phosphorylate Cav1 on its tyrosine 14 residue (99,100). Caveolin-1 consists of
hydrophobic N- and C-terminal domains, both of which are cytosolic. Three
palmitoylation sites in the C-terminal region next to the transmembrane domain
contribute to anchoring caveolin proteins to the membrane. The N-terminal region of all
caveolins contains a conserved FEDVIAEP motif that has been defined as the ‘caveolin
signature’ sequence, and has been suggested to be important for the binding of caveolin
to cholesterol- and glycosphingolipid-rich membrane domains (101). The central
segment of caveolin proteins contains the scaffolding domain, which allows
oligomerization of caveolin monomers (forming complex comprised of 14-16
monomers) and direct interaction with other proteins, like Src family tyrosine kinases,
growth factor receptors, endothelial nitric oxide synthase, G proteins and G-protein-
coupled receptors, presumably regulating their activity (102,103). In addition, caveolin
proteins contain several serine and tyrosine residues within their intracellular domains
that are substrates for a variety of kinases, and become phosphorylated in response to
different stimuli (104,105).
Cav-1 localizes to plasma-membrane caveolae and also to the Golgi apparatus and
trans-Golgi-derived transport vesicles (106,107). Cav-1 may have a soluble cytoplasmic
form, as well as a secreted form, depending on the cell type (108), and the first 31
amino acids may be important in selectively targeting isoforms of Cav-1 to different
cellular compartments (109).
As previously stated, caveolin-1 is essential for caveolae formation and a threshold
level of Cav-1 is required to generate caveolae at the plasma membrane (93). Though, it
is important to note that caveolin-1 can form functional microdomains at the plasma
membrane independently of its ability to form caveolae (110). Caveolin-1 also plays an
essential role in lipid uptake and regulation (111), transcellular transport and signaling
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in endothelial cells (112), but also for the entry of certain viruses into mammalian cells
(113,114). The abundance of caveolae in endothelial cells led to the characterization of
a role for Cav-1 in caveolae formation and endocytosis, particularly transendothelial
transport (115,116).
Figure 3. Structure of caveolin-1. Cav-1 contains a hydrophobic central
domain with a hairpin-like conformation inserted in the inner leaflet of the
plasma membrane. 14-16 Cav-1 monomers form a single cav-1
homooligomer. A simplified dimmer is illustrated here. Both the COOH and
NH2 terminus of the cav-1 monomer face the cytoplasm. The caveolin
scaffolding domain is located between amino acid residues 82-101 in the
NH2-terminal region adjacent to the hydrophobic membrane-insertion
domain. The COOH-terminal region of cav-1 contains 3 palmitoylated
cysteine residues. Inset: caveolae viewed by electron microscopy (×50,000).
(From Yang Jin and Augustine M. K. Choi, 2011)
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Caveolin-1 and tumor progression
Several pieces of evidence indicate that caveolin-1 influences the development of
human cancers. However, the exact functional role of caveolin-1 is still controversial.
Caveolin-1 expression increases with cell differentiation. For example, exposure of pre-
adipocytes to differentiation-inducing agents induces caveolin-1 mRNA and protein
expression (117). Moreover, in addition to endothelial cells, Cav-1 is highly expressed
in terminally differentiated cells such as adipocytes, pneumocytes, chondrocytes and
smooth muscle cells. Thus, consistent with its anti-proliferative activity, it appears that
cell differentiation is accompanied by increased expression of caveolin-1 and caveolae
(118). Evidence of an inverse relationship between caveolin-1 expression and
transformation was first reported in 1995, with the observation that transformation of
NIH-3T3 by Abl and Ras oncogenes led to decreased cellular levels of Cav-1 (119). A
few years later a direct link between Cav-1 expression and transformation was
established when restoration of caveolin-1 expression in the same Abl- or Ras-
transformed NIH-3T3 cells was sufficient to abrogate their anchorage-independent
growth (120). In NIH-3T3 fibroblasts, antisense inhibition of caveolin-1 expression is
sufficient to induce the oncogenic transformation. It also activates MAPK expression
and stimulates anchorage-independent-growth (121). The tumor suppressor effect of
caveolin-1 was later confirmed in breast cancer cells (122), in tumorigenic cell hybrids
(123), in lung alveolar epithelial cells (124), in squamous cell carcinoma (125), and in
transformed fibroblasts in which the c-Myc oncoprotein was found to transcriptionally
repress Cav-1 expression (126). The development of Cav-1 depleted knockout mouse
models confirmed the “transformation suppressor” function of caveolin-1. Loss of
caveolin-1 is required to accelerate tumorigenesis and metastasis: PyMT/Cav-1 (-/-)
mice showed accelerated onset of mammary tumors and lung metastasis (127). The
human genes encoding Cav-1 were localized to the q31.1-q31.2 region of the
chromosome 7 at the D7S522 locus. Interestingly, this locus is frequently deleted in a
variety of human cancer types including prostate, breast, renal cell carcinoma, and
ovarian adenocarcinomas (128). Also, a sporadic mutation in the caveolin-1 gene, at
codon 132 (P132L), has been found in 16% of human breast cancer. This mutation
behaves in a dominant-negative manner, explaining why only a single mutated Cav-1
allele is found in patients with breast cancer, and leads to formation of misfolded Cav-1
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oligomers that are retained within the Golgi complex and are not targeted to caveolae
(129).
Although its negative role in transformation has been demonstrated using both in vitro
and in vivo models, there is accumulating evidence that caveolin-1 does not have the
same function in all types of tumor. Clinicopathological analysis of human pancreas,
esophageal, breast, renal cell, brain, lung, and prostate cancer reveal that Cav-1
upregulation is correlated with reduced survival. However, consistent with the tumor
suppressor role attributed to caveolin-1, decreased Cav-1 levels are observed in cancer,
relative to normal human breast, lung, ovary, thyroid, and mesenchimal tissues.
Furthermore, the association of Cav-1 expression with tumor progression is variable in
studies of colon, renal cell and oral carcinomas (118). One way to reconcile the
conflicting data is to consider the possibility that the role of caveolin-1 may depend on
tumor stage. For example, the pattern of caveolin-1 expression in benign prostatic
epithelium and human prostate cancer is consistent with tumor suppressive activity
(130). Similarly, Cav-1 expression is reduced in breast tumors relative to normal tissue
with only a minority of tumors, mainly representing late, advanced stages, including but
not limited to inflammatory breast cancer, showing caveolin-1 positivity and poor
prognosis, which most likely is a consequence of hypomethylation of its promoter (131-
134).
Several studies also reported a correlation between caveolin-1 expression and metastasis.
Expression of caveolin-1 in a highly metastatic carcinoma-derived cell line suppressed
lung metastasis in vivo and reduced invasion in vivo. Decreased invasion in caveolin-1
expressing cells was accompanied by reduction in MMP9 and MMP2 secretion and
gelatinolitic activity, and reduced ERK 1/2 signaling in response to growth factors (127).
Caveolin-1 potentially restrains tumor cell growth and metastatic potential. Cav-1 re-
expression in human breast cancer and in colon carcinoma cell lines inhibited tumor cell
growth (122), reduced tumorigenicity (135), negatively affected in vivo tumor growth,
metastasis development and invasiveness in metastatic mammary tumor cells and
promoted cell-cell adhesion in ovarian carcinoma cells by a mechanism involving
inhibition of Src kinases (136).
On the other hand, there is increasing evidence to suggest that the caveolins and
caveolae may also be involved in shifting the tightly regulated balance from anti-
apoptotic to pro-apoptotic signaling. Caveolin-1 has been shown to interact and
inactivate a number of signaling molecules involved in survival/proliferation, such as
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the PDGF receptor and phosphatidylinositol 3-kinase (PI3K) (137-139). However, aside
from this seemingly pleiotropic suppression of plasma-membrane-initiated pro-survival
pathways, caveolae and the caveolins appear to have a highly specialized role as well.
Ceramide is an essential factor for commitment to apoptosis induced by several cellular
stress factors (140). Interestingly, sphingomyelin, the precursor to ceramide generation,
is one of the most abundant lipids in caveolae microdomains (141). Furthermore,
overexpression of caveolin-1 determines inhibition of PI3K signaling and sensitizes
cells to ceramide-induced cell death (139). Therefore, the production of ceramide and its
downstream actions seem to depend on caveolar localization and caveolin-1 regulation.
In support of these results, overexpression of caveolin-1 sensitizes cells toward
apoptotic stimuli, whereas antisense-mediated down-regulation of caveolin-1 imparts
resistance to apoptosis (142).
Caveolin-dependent signaling and glycosphingolipids
Caveolin-1 regulates cell fate thanks to its ability to bind various signaling molecules.
This observation led researches to propose that caveolins constitute a family of
scaffolding proteins that organize “preassembled signaling complexes” at the plasma
membrane by locally increasing the concentration of signal transducers and by
regulating the activation state of caveolae-localized signaling molecules (143). As
discussed previously, caveolin-1 and sphingolipid-rich membrane complexes are
dynamically interacting and interdependent in their compositional regulation. So far, at
least two different mechanisms can be hypothesized to explain the effects of
glycosphingolipids on signaling complexes organized by caveolin-1. First, both
caveolin-1 and glycosphingolipids are simultaneously required in some cases to
organize the molecular architecture of a signaling complex. This seems the case for
EGFR: for this receptor the formation of a signaling complex with caveolin-1,
tetraspanin CD82 and GM3, probably in noncaveolar membrane regions, allows the
interaction of EGFR with activated PKC-α, ultimately leading to the inhibition of EGFR
signaling (84,144-147). However, this signaling complex does not seem to require a
direct caveolin-GM3 interaction (84). Second, in other cases, caveolin-1 and
sphingolipids can compete for a common interactor. This is exemplified by insulin
receptor (IR), which can form complexes with caveolin-1 required for insulin signaling
leading to the translocation of GLUT4 at the surface of normal adipocytes (148).
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Accumulation of GM3 upon acquisition of insulin resistance leads to the displacement
of IR from caveolin-1 complex and its sequestration as a complex with GM3 (149). In
this case it has been convincingly demonstrated that a direct GM3-IR interaction is
required. Increased GM1 cellular levels lead to the displacement of another growth
factor receptor, PDGFR, located in caveolae, negatively regulating Src mitogenic
signaling. However, in this case it is not known whether the formation of a PDGFR-
GM1 complex is required for its uncoupling from caveolae. Since caveolin-1 can
directly bind sphingolipids, it cannot be excluded that in this case GM1 forms a
complex with caveolin-1, or that enrichment in GM1 inside the caveolae induces a deep
reorganization of caveolar membrane, thus excluding PDGFR from caveolae (150).
The examples reported above illustrate how caveolin-1 and glycosphingolipids could
cooperate or compete in the multimolecular organization of a membrane receptor with
its interactors, thus potentially affecting the coupling of the receptor with the
downstream signaling events and regulating the receptor activity. Another way to
regulate receptor function that can be influenced by both caveolin and sphingolipids is
represented by the downregulation of plasma membrane receptor concentration through
its internalization. The internalization of plasma membrane components, including basal
state, ligand-activated or transactivated receptors, can exploit different routes whose
complexity has been only recently and partially unveiled. This usually leads to
important consequences for the receptor activity, encompassing its sequestration in
intracellular sites, recycling to the plasma membrane, intracellular degradation or
translocation to the nucleus. Internalization of receptors occurs via clathrin-dependent
and clathrin-independent pathways (151). Both mechanisms are involved in the removal
of receptor tyrosine kinases (RTK) from the plasma membrane upon ligand activation.
Clathrin-dependent endocytosis represents a single traffic pathway well characterized in
its step and molecular aspects. On the other hand, clathrin-independent endocytosis
encompasses several different pathways that are much more poorly understood in their
molecular mechanisms and physiological significance. Among those, caveolin-1-
dependent, cholesterol-sensitive endocytic mechanism is usually referred to as “caveolar
endocytosis”. Caveolar endocytosis is dependent not only on caveolin-1, but also on
caveolae, and endothelial caveolae contain the whole array of molecular components
for a vesicular transport system (152). Lipid raft-dependent (cholesterol- and
sphingolipid-sensitive) but caveolin-1-independent internalization pathways have also
been described. This picture is still fragmentary, but it becomes apparent that caveolae-
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and lipid rafts-dependent endocytosis are similar but distinct processes, that are
interdependent and reciprocally regulated (153,154). The situation is made even more
complex by two relevant observations: 1) association of a molecule with lipid
rafts/caveolae does not necessary imply its internalization via a caveolae/lipid raft-
mediated pathway. Multiple endocytic pathways have been described for the
internalization of lipid raft markers, as well exemplified by the case of cholera toxin,
that can be internalized via caveolae but also via caveolae/raft-independent mechanisms,
including clathrin-dependent endocytosis, despite its initial binding to GM1 within lipid
raft (155-158); 2) usually the internalization of lipid raft components via the clathrin-
mediated mechanism requires that they move outside caveolae/lipid rafts compartment.
However, in some cases, lipid raft recruitment is an essential prerequisite for clathrin-
dependent endocytosis, indicating that the association with lipid rafts can modulate as
well lipid raft independent internalization mechanisms (159,160). Under basal
conditions, caveolae are relatively immobile structures with a low turnover at the
plasma membrane levels (161), and are thus probably not heavily involved in
constitutive endocytic trafficking. However, caveolae (and caveolin) can be mobilized
and internalized upon specific stimuli (e.g., antibody mediated cross-linking of GPI-
anchored alkaline phosphatases (116) and of major histocompatibility complex class I
(MHC I) (16), cell membrane attachment of SV40 virus (114), disengagement of
integrin receptors upon cell detachment (162)). Based on the observations that the loss
of caveolin-1 does not impair endocytosis of some lipid raft markers (163) and that
caveolin-1 levels inversely correlate with the uptake of raft-associated receptors (e.g.,
reduction of caveolin levels accelerate raft-mediated internalization of autocrine
motility factor receptor (164)), it has been proposed that caveolin-1 could indeed act as
a negative regulator of caveolae/raft-mediated receptor uptake, stabilizing and
immobilizing potentially endocytic raft domains (153,154). Triggering of caveolae/raft-
mediated internalization would thus require additional factors allowing to overcome the
restraint to endocytosis imposed by caveolin-1. It has been shown that caveolae/rafts
internalization in response to specific stimuli is dependent on glycosphingolipids and
tyrosine phosphorylation. Sphingolipids are essential for clathrin-independent
endocytosis (165), and glycosphingolipids stimulate caveolar endocytosis (166).
Glycosphingolipids could directly affect the membrane environment of caveolin-1, or
could regulate tyrosine phosphorylation of caveolin-1, that is essential requirement for
caveolar/raft endocytosis (162). Indeed, using fluorescent sphingolipids analogues it has
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been proven that sphingolipid segregation in endocytic vesicles is essential for caveolar
endocytosis. On the other hand, glycosphingolipids-stimulated caveolar endocytosis
required Src activity, and addition of exogenous sphingolipids or cholesterol has been
shown to stimulate cholesterol activity (167). Thus, likely multiple mechanisms
regulated by sphingolipids are potentially responsible for triggering caveolar
endocytosis.
Along this line, another mechanism that could be involved in glycosphingolipid-
regulated and caveolin-mediated clearance of plasma membrane receptors is suggested
by the observation that many RTKs are at least in part localized in lipid rafts, have a
caveolin binding motive and form complexes with caveolin-1. In all these cases, the
elevation of cellular gangliosides levels has as a consequence the shift of the receptor
outside of caveolae. In the case of IR and PDGFR, this results in the uncoupling of the
receptor from the downstream signaling cascade. However, as mentioned above,
movement of RTKs outside caveolar membrane domains potentially target these
receptors to clathrin-dependent internalization pathways, thus contributing in the
negative regulation of the cell surface concentration of the receptor.
Src kinases
Src tyrosine kinases
Tyrosine kinases play important roles in controlling animal-specific cellular functions
such as rapid cell-cell communication via the plasma membrane. The most critical
feature of tyrosine kinases is the strict regulation of their functions. Due to these
enzymes' importance in controlling cellular function, dysregulation of tyrosine kinases
can play a causative role in various diseases, especially cancers. Tyrosine kinases are
classified into two major subgroups: receptor and non-receptor. The Src family tyrosine
kinases (SFKs) are the major non-receptor tyrosine kinases expressed in multiple types
of animal cells and are involved in many of the signaling mechanisms associated with
G-protein-coupled receptors, integrins, receptor tyrosine kinases, T-cell receptors, and
others (168). The members of the Src family tyrosine kinases include Src, Yes, Fyn,
Lyn, Blk, Fgr, Hck, and Lck. Of the members of the family, c-Src, Yes, and Fyn are
expressed ubiquitously, with the other members being expressed primarily in
lymphocytes (169). SFKs all share a common general structural organization: an N-
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terminal membrane association domain, a unique domain, a Src homology (SH) 3
domain, an SH2 domain, a catalytic domain, and a C-terminal regulatory domain. The
N-terminal domain contains signals for lipid modification: myristoylation (in all SFKs)
and palmitoylation (in all but c-Src and Blk) signals, both of which are required for
membrane association of SFKs. In particular, palmitoylation has been implicated in the
stable localization of SFKs in lipid rafts (170). All SFKs share the SH3 and SH2
domains, the catalytic domain and the C-term tail. The catalytic domain contains an
autophosphorylated tyrosine (Y416 in c-Src), which is phosphorylated when the enzyme
is active. SH2 domains bind phosphotyrosine motifs, and SH3 domains bind prolin-rich
motifs. In the inhibited state, the SH2 domain of c-Src is involved in an intramolecular
interaction with a C-terminal regulatory domain phosphotyrosine (Y527) locking the
enzyme in an inactive or closed state (171). In the case of v-Src, oncogenic activation
results from the loss of this C-terminal regulatory domain (172). Phosphorylation of the
C-terminal regulatory tyrosine is catalysed by C-terminal Src kinase (Csk) (173). Csk
knockout mice die at embryonic day 9 or 10, therefore it has been hypothesized that Csk
might be required for normal development (174). The structure of Csk is similar to
SFKs with an SH2 domain, an SH3 domain, and a kinase domain. It is known that Csk
lacks a regulatory C-terminal tyrosine, N-terminal myristoylation, and membrane
association domain (173). Although SFKs are membrane-associated and regulated by
phosphorylation, Csk is intrinsically cytoplasmic and requires membrane adaptors to
inhibit membrane-associated SFKs (175). On the other hand, in the case of c-Src,
activation of growth-factor receptors leads to their association with the SH2 domain,
which disrupts inhibitory intramolecular interactions to promote c-Src activation. Other
proteins, such as CRK-associated substrate (CAS) and FAK, bind to the c-Src SH2 and
SH3 domains to promote c-Src activation by a similar mechanism. Levels of c-Src
protein are also negatively regulated by the E3 ubiquitin ligase CBL, which leads to c-
Src ubiquitylation and subsequent degradation by the proteasome (176).
The localization of c-Src within the cellular infrastructure is important. The association
of c-Src with the plasma membrane is considered essential for cellular transformation
(177), and the autophosphorylation of Tyr419 that occurs with membrane targeting,
which is enabled by interactions with activated receptor tyrosine kinases, is associated
with the highest level of c-Src transforming activity (178). Inactive c-Src is localized at
perinuclear sites, but c-Src activation causes its SH3 domain to become indirectly
associated with actin. Activated c-Src is ultimately translocated to the cell periphery to
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sites of cell adhesion, where it attaches to the plasma membrane inner surface through
its myristoylated domain (177). This tethered location allows for interactions with
membrane-bound receptor tyrosine kinases and integrins associated with adhesion
functions. The localization of c-Src at the membrane-cytoskeletal interface in focal
adhesions, lamellipodia and filopodia seems to be regulated by RhoA, Rac1 and Cdc42
(179).
Figure 4. Proposed model for Src activation. The left panel represents the
inactive conformation of Src, in which Tyr 527 interacts with the SH2
domain, positioning the SH3 domain to interact with the linker between the
SH2 and catalytic domains. The middle panel illustrates different
mechanisms involved in the activation of Src, and the right panel represents
the open or active conformation (Martin, G.S., 2001).
Src family kinases and tumor
Because SFKs are pleiotropic kinases involved in many cellular events, it is not
surprising that aberrant activation of Src signaling contributes to diverse aspects of
tumor development (176). SFKs are important mediators of tumor cell proliferation and
survival. The most prominent and well-studied function of Src is its extensive
interaction with transmembrane receptor tyrosine kinases (RTKs) at the cell membrane
via its SH2 and SH3 domains (180). Src has long been known to interact with epidermal
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growth factor receptor (EGFR) (181), human epidermal growth factor receptor 2 (HER2)
(182), platelet-derived growth factor receptor (PDGFR) (183), and insulin-like growth
factor receptor (IGF-1R) (184). Through these interactions, Src integrates and regulates
RTK signaling and directly transduces survival signals to downstream effectors such as
PI3K, Akt and signal transducers and activator of transcription 3 (STAT-3) (185). Src
can also be activated by other membrane receptors including integrins and
erythropoietin receptor (EpoR). Src is also known to be crucial during tumor metastasis,
mainly as a result of its role in regulating the cytoskeleton, cell migration, adhesion and
invasion (186). Through interaction with p120 catenin, Src activation promotes
dissociation of cell-cell adherens junction and facilitates cell mobility (176). Through
phosphorylation of focal adhesion kinase (FAK), Src activation also stabilizes focal
adhesion complexes, which consist of FAK, paxillin, RhoA and other components, and
enhances cell adhesion to extracellular matrix (186). Additionally, Src also plays a part
in regulating the tumor microenviroment. Under hypoxic conditions, Src activation
promotes angiogenesis through stimulation of vascular endothelial growth factor
(VEGF) (187), matrix metallopeptidases and interleukin-8 (IL-8) expression (188).
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Figure 5. Effects of c-Src on tumor cell behavior. c-Src exerts its effects on
tumor-cell behavior through a range of mechanisms mediated by interactions with
various substrates and binding partners. A selection of these mechanisms is
illustrated here. c-Src promotes motility and invasiveness stimulating E-cadherin
ubiquitylation and its subsequent endocytosis, and also by stimulating turnover of
focal adhesions in various ways. The binding and activation of FAK, which
phosphorylates substrates such as paxillin, CAS and p190 Rho-GAP bring about
changes in the cytoskeleton that lead to focal-adhesion disruption. c-Src also
brings about similar changes independently of FAK through its interactions with
cytoskeleton-associated proteins such as p120 catenin and cortactin. Ras
phosphorylation by c-Src inhibits integrin function, which also leads to focal
adhesion turnover. c-Src activity also leads to changes in the expression of several
genes that contribute to tumor progression. Activation of FAK stimulates the c-
Jun N-terminal kinase (Jnk) signaling pathway, leading to increased expression of
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the matrix metalloproteinases MMP2 and MMP9; c-Src also induces the
expression of various tissue inhibitors of metalloproteinases (TIMPs). MMPs
promote the breakdown of the extracellular matrix. STAT3 by c-Src leads to
increased expression of VEGF, a signaling molecule that promotes tumor
angiogenesis (Yeatman, T., 2004).
Caveolin-1 and c-Src
It has been shown that caveolin-1 promotes cell-cell adhesion in ovarian carcinoma cells
by a mechanism involving inhibition of Src kinases (189). Non-receptor tyrosine
kinases of the Src family are involved in several cell functions such as mitogenic
response of growth factors, fibroblasts cell migration and epithelia cells scattering in
cancers (168). Src kinases, located at the inner face of membranes, segregate in the
specific membrane domains defined by sphingolipids, and usually enriched in caveolin.
Src kinase localization in caveolae and/or sphingolipid-enriched domains seems to be
instrumental for growth factor-induced Src dependent mitogenic response (170,177).
Src kinase are activated and involved in cancer progression and metastasis of most
human carcinoma. Publishes results from our group show that c-Src is in a less active
state in low-motility human ovarian carcinoma cell lines expressing high levels of GM3
and caveolin-1 (4). Remarkably, it has been demonstrated that Src kinases are activated
in colon cancers despite the expression of the C-terminal Src kinase, Csk, the main
negative regulator of c-Src and other related kinases (190). Csk is a cytosolic enzyme
that may need an intermediary protein to locate in Src kinases vicinity. Several
candidates have been described such as paxillin, Csk binding protein/phosphoprotein
associated with glycosphingolipids (Cbp/PAG), and caveolin-1. When Cbp/PAG is
phosphorylated on tyrosine 314 by active SFKs, Csk is recruited to lipid rafts via
binding to Cbp at pY314 and phosphorylates tyrosine 527 to inactivate the catalytic
activity of SFKs. The inactivated SFKs then relocate to non-raft compartments (173).
Cbp/PAG is downregulated in metastasis. Cbp/PAG could play a major role in Src
kinases regulation and cancer progression either as a Csk binding protein or as a
glycolipid interacting protein. On the other hand, interactions of Src with caveolin-1
have important consequences. Caveolin-1 seems to act as a membrane adapter which
couples integrin receptor to Src kinases (191). Src induces phosphorylation of caveolin-
1 at tyrosine 14, which is responsible for the rearrangement of caveolin-1 within the cell
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(105,192). On the other hand, caveolin-1 phosphorylation is involved in the regulation
of the docking of Csk, the negative regulator of Src, suggesting a mechanism of
negative regulation of Src activity by phosphorylated caveolin (193). Moreover,
phosphorylated caveolin is recruited to lipid-enriched membrane domains upon integrin
receptor disengagement, inhibiting the internalization of these specialized membrane
areas and the signaling events downstream to integrin receptor (194-196).
Integrins
Integrin structure
Cells make extracellular matrix, organize it, and degrade it. The matrix in its turn exerts
influences on the cells through transmembrane cell adhesion protein that can act as
matrix receptors and tie the matrix to the cell cytoskeleton. However, their role goes far
beyond simple passive mechanic attachment. In fact, cell adhesion to the extracellular
environment has an essential role in cell survival, growth and migration. Although
several types of molecules can function as matrix receptors or co-receptors, including
transmembrane proteoglycans, the principal receptors on animal cells for binding most
extracellular matrix proteins are the integrins.
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Figure 6. The subunit structure of integrin. Electron micrographs suggest that
the molecule has approximately the shape shown here, with the globular head
projecting more than 20 nm from the lipid bilayer. By binding to a matrix protein
outside the cell and to the actin cytoskeleton inside the cell, the protein serves as a
transmembrane linker. The α and β subunits are held together by noncovalent
bonds. The α subunit is made initially as a single polypeptide chain, which is then
cleaved into one small transmembrane domain and one large extracellular domain
that contains four divalent-cation-binding sites; the two domains remain held
together by a disulfide bond. The extracellular part of the β subunit contains a
single divalent-cation-binding site, as well as a repeating cysteine-rich region,
where intrachain disulfide bonding occurs.
Integrins are a family of glycosylated, heterodimeric transmembrane adhesion receptors
that consist of noncovalently bound α and β subunits (197). In vertebrates, 18 α subunits
and 8 β subunits have been discovered, which combine into 24 different heterodimers
that recognize overlapping but distinct sets of extracellular ligands (198). Most integrins
recognize several ECM proteins. Conversely, individual matrix proteins, such as
fibronectin, laminins, collagens, and vitronectin, bind to several integrins (199). At least
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eight types of integrins bind fibronectin, and at least five types bind laminin. Because
the same integrin molecule in different cell types can have different ligand-binding
specificities, it seems that additional cell-type-specific factors can interact with integrins
to modulate their binding activity (200).
Figure 7. Integrin family. Integrins are loosely grouped into three classes
that bind basal extracellular matrix (ECM), provisional ECM and cell
surface adhesion molecules (CAMs), respectively. Basal ECM mainly
includes collagen and laminin. Provisional ECM mainly includes fibrinogen,
fibronectin, vitronectin, cryptic collagen and von Willebrand factor. The α I-
containing integrins are asterisked (Zhang, K. et al., 2012).
Through interaction with the ECM, integrins control many cellular processes that occur
during development and in the progression of diseases such as cancer. As well as
mediating attachment to the ECM, integrins act, directly or indirectly, as bidirectional
transducer molecules (201,202). Although they lack any known enzymatic activity of
their own, integrins can initiate “outside-in” signaling by recruiting signaling moieties
that generate and convey signals to the migratory and proliferative machinery of the cell.
Another way in which integrins can convey outside-in signals is through their ability to
influence the manner by which growth factor receptor respond to their ligands (203).
Integrin function can also be controlled from within the cell through “inside-out”
signaling (201). Indeed, integrins can be switched from low-affinity conformation to a
high-affinity active conformation through the association of the β-integrin cytoplasmic
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tail with proteins such as talin and kindling. This process is important for the
coordination of adhesion during the migration of various cell types (204).
Integrin signaling and lipid rafts
Examples of signaling pathways that involve lipid rafts include immunoglobulin E
signaling, T lymphocyte activation, glia cell line-derived growth factor (GDNF)
signaling and H-Ras mediated Raf activation (17). In all these signaling events, the
interaction between the activated receptors and their immediate downstream effectors
takes place in the raft fraction of the plasma membrane, and downstream signaling is
inhibited by cholesterol depletion. Recent work in this area has focused on the
activation of signaling by the small GTPase Rac in response to integrin-mediated cell
adhesion to extracellular matrix. Rac is implicated in cell survival, gene expression, cell
cycle progression, cell migration, and cell-cell adhesion and its activation by integrins
upon fibronectin binding induces GTP loading, similar to the activation triggered by
growth factor receptors; but, distinct from growth factor regulation, integrins also target
Rac to specific plasma membrane microdomains, where Rac can interact with its
downstream effector molecule PAK to induce signaling (205,206). Thus, when the
fibronectin binding integrins are uncoupled from downstream signaling by detaching
cells from the ECM, PAK is not activated by Rac, even though Rac-GTP is still present
in these detached cells (206). These data suggests that integrin-mediated adhesion
facilitates the coupling of Rac to PAK by modulating the plasma membrane so as to
target Rac to specific microdomains, where the interaction with its effector can take
place. There is strong evidence that the membrane microdomain targets of integrin-
modulated Rac affinity are lipid rafts or cholesterol-enriched membrane microdomains
(CEMM). Not only the association of Rac with CEMM has been reported in several
studies (162,207,208), it has also been reported that the loss of integrin signaling
promoted by cell detachment induces a rapid CEMM internalization mediated by
caveolae, and this prevents the targeting of Rac to the plasma membrane and its
coupling to PAK (162). These data suggest a model in which integrin-mediated cell
adhesion promotes plasma membrane localization of Rac and its subsequent coupling to
its effector by preventing internalization of the Rac-containing CEMMs (162). Evidence
for association with CEMMs in an integrin-dependent manner has also been reported
for the other two members of the Rho family of GTPases, Rho and Cdc42 (208-210).
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Rho and its effectors regulate microtubule stabilization, and this process occurs only at
the leading edges of migrating cells, which are enriched in Rho and CEMMs. The local
coupling between Rho and its effector is regulated by integrin-mediated cellular
adhesion to the ECM, and appears to require active signaling by focal adhesion kinase
(210). Cdc42 targeting to the plasma membrane is also integrin-dependent (205).
Glycosphingolipids and integrins
One mechanism by which glycosphingolipids could affect cell adhesion and migration
is via their interaction with integrins. Glycosphingolipids have been shown to directly
modulate integrin-based cell attachment. For example, gangliosides enhance binding of
integrins to the ECM in mouse mammary carcinoma, melanoma, and neuroblastoma
cells (211-213). Several models have been proposed for the mechanisms by which
glycosphingolipids or glycosphingolipid-enriched microdomains may regulate integrin
function (214,215). First, glycosphingolipids could initiate signaling events, which
cause downstream activation of integrins. Indeed, addition of exogenous
glycosphingolipids to cells has been shown to have significant effects on signaling
cascades. Another possibility is that glycosphingolipids promote clustering of integrins
in glycosphingolipid-enriched microdomains, thus increasing their avidity for ligand.
The cross-linking of integrins with certain antibodies is an established method for
integrin activation (216,217). Similarly, integrin function can be modulated by antibody
cross-linking of cholera toxin B subunit bound to GM1 or GPI-linked proteins
(214,215). However, no studies have provided direct evidence that glycosphingolipids
modulate integrin clustering in glycosphingolipid-enriched microdomains in the
absence of cross-linking agents. An additional mechanism by which glycosphingolipids
could regulate integrins is by affecting their endocytosis from the plasma membrane.
Recent studies have shown that some integrins can be internalized via caveolae
(217,218), a subset of glycosphingolipid-enriched microdomains defined as
invaginations at the plasma membrane enriched in caveolin-1 (16,95). Caveolae are
sites for clathrin-independent endocytosis of glycosphingolipids as well as some viruses
and bacteria toxins (42,114,166,167). When cells are attached to the ECM, integrins
negatively regulate caveolae internalization, preventing uncoupling of signaling
molecules such as Rac disengagement from its effector PAK. It has been reported that at
least three integrin-dependent growth pathways (Ras/Erk, PI3K/Akt, Rac/PAK) are
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impaired by Cav-1 mediated CEMM internalization. The presence of caveolin thus links
integrin to growth-regulatory pathways; alterations of this regulatory mechanism in the
absence of caveolin would uncouple integrins from growth-regulatory pathways and
therefore break the requirement of integrins for active signaling, resulting in anchorage
independent growth, characteristic of most tumor cells. In addition integrins regulate the
focal adhesion localization of tyrosine phosphorylated caveolin-1, preventing its
recruitment to caveolae and internalization (194,219).
Figure 8. Integrins and caveolae. When cells are adherent, integrin
engagement with fibronectin leads to the retention of phosphorylated
caveolin in focal adhesions (1), which opposes the endocytosis of lipid rafts.
Cell detachment triggers the release of phosphorylated caveolin from focal
adhesions (2), thus allowing its association with caveolae to induce the
endocytosis of lipid rafts (3). Re-engagement of α5β1 integrin (1) reverses
this process, both by sequestering phosphorylated caveolin to shut down
lipid raft internalization and by activating ADP-ribosylation factor 6 (ARF6)
to promote rapid recycling of lipid rafts, which recruits active Rac to the
plasma membrane (4) (Caswell, P. et al., 2009).
It was also reported that the addition of glycosphingolipids or cholesterol to the plasma
membrane of cells stimulates caveolar endocytosis via activation of Src kinase (166).
After treatment with exogenous sphingolipids the cells began to reorganize their actin
cytoskeleton and retract, suggesting a link between the plasma membrane
glycosphingolipid and cholesterol composition and cell adhesion via integrins.
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A growing number of evidence suggests that alterations in glycosphingolipids
expression and metabolism are common in tumors of different origins. Moreover,
gangliosides, sialic acid-containing glycosphingolipids, are known to modulate several
cellular functions relevant to tumor progression. Thus, altered ganglioside expression
might play a relevant role in determining the aggressiveness and metastatic potential at
least in certain tumors. Cellular ganglioside levels deeply affect tumor cell adhesion,
motility and migration. In particular, gangliosides might contribute to the modulation of
integrin-dependent interactions of tumor cells with the extracellular matrix as well as
with host cells present in the tumor microenvironment. Therefore, the influence of
gangliosides on tumor cell adhesion and motility seems to be mediated by the regulation
of membrane-associated signaling complexes. Gangliosides interaction with
hydrophobic membrane adaptor proteins seems to be crucial for this regulation. From
this point of view, the interaction between gangliosides and the integral membrane
protein caveolin-1 is potentially very interesting. Caveolin-1 is usually highly expressed
in terminally differentiated cells, while it is markedly down-regulated in tumors of
different origin, including ovarian, breast and colon carcinoma. It has been recently
demonstrated that in human ovarian cancer cells overexpressing GM3 synthase, an
enzyme involved in the synthesis of complex glycolipids, invasiveness is reduced. It has
been shown that in cells with high levels of GM3 synthase, a complex organized by
caveolin-1, a hydrophobic membrane protein first identified as the main component of
caveolae, regulates cell motility and adhesion by controlling the inactivation of c-Src
downstream to integrin receptors.
On the basis of these considerations, the aim of the present study was to investigate the
role of gangliosides as modulators of membrane signaling complexes organized by
caveolin-1, able to affect the adhesion, motility and invasiveness of human cancer cells,
thus contributing to a better understanding of the role of membrane glycolipids in the
early mechanisms of the progression and dissemination of human cancer.
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Chemicals
Commercial chemicals were the purest available and, unless otherwise stated, were
purchased from Sigma Chemical Co.
Lipids and radioactive lipids
GM1, GM2 and GD1a were prepared from the bovine brain ganglioside mixture and
purified by partitioning (220). GM3 was prepared from GM1 using the GM1-lactone
hydrolysis procedure (221). [1-3H]sphingosine (radiochemical purity over 98%; specific
radioactivity 2.2 Ci/mmol) was prepared by specific chemical oxidation of the primary
hydroxyl group of sphingosine followed by reduction with sodium boro[3H]hydride. [3H]
lipids used as chromatographic standards were prepared from [1-3H]sphingosine-fed
cell cultures as previously described (227).
Cell lines and culture
Human ovarian carcinoma A2780 cells were kindly provided by Dr. Franca Formelli
(Department of Experimental Oncology, National Cancer Institute, Milan, Italy) and
were obtained by Dr. R.F. Ozols (National Cancer Institute, Bethesda, USA). These
cells grow as monolayers on an artificial substrate and were cultured in RPMI 1640
medium (Sigma) supplemented with 10% of heat-inactivated fetal bovine serum
(Invitrogen), 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, at 37°C
with 5% of CO2.
The cell line A2780/HPR, resistant to the drug HPR, was obtained from the parental
cells A2780 through in vitro administration with increasing sub-lethal concentrations of
HPR (Sigma). The cells that survived to 60 selection cycles in HPR containing medium
were cloned through limit dilution.
The A2780/HPR clones can survive in presence of HPR at a concentration 10 times
higher than the ones used on A2780 cells in the same experimental conditions (222).
HPR resistance in these clones is reversible; it was observed that A2780/HPR cells
cultured for 5 passages in complete medium without the drug show a marked decrease
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in their resistance. For this reason, A2780/HPR cells are grown in complete medium
containing 5 μM HPR.
The cell line A2780/SAT-I was obtained by transfection of the parental cells with the
cDNA of the sialyltransferase-I (SAT-I) enzyme), also known as GM3 synthase. A2780
cells were transfected with the pRc/CMV expression vector (223), or with an empty
vector. The clones stably transfected were isolated using 750 μg/ml of geneticin (G418,
Sigma). The A2780/SAT-I cells were cultured in complete medium containing 250
μg/ml of geneticin.
RNA extraction and RT-PCR
Total RNA was isolated by single-step acid-guanidine-isothiocyanate-chloroform
extraction methods and purified by PureLinkTM Macro-to-Midi kits (Invitrogen),
according to manufacturer’s instructions. Five micrograms of RNA was treated with 3
U of RNase-free DNase for 25 min at room temperature to remove possible DNA
contamination. The total amount of extracted RNA was estimated by a quantitative
fluorescent method using the Quant-iTTM RiboGreen RNA Reagent Kit (Invitrogen).
Using random hexamers, 1 μg of RNA were reverse-transcribed using SuperScriptTM III
First-Stand Synthesis System for RT-PCR (Invitrogen) in a final 20 μl reaction volume.
cDNA representing 50 ng of total RNA was adapted as a template for RT-PCR.
For multiplex RT-PCR, we used a mixture containing 0.2 μM primers, AccuPrimeTM
PCR Buffer, and 1 unit of AccuPrimeTM Taq in a final volume of 50 μl. The
amplification was performed using the following cycle conditions: initial denaturation
at 94 °C for 2 min, followed by 35 cycles of 15 s at 94 °C (denaturation), 20 s at 58 °C
(annealing) and 30 s at 68 °C (elongation). RT-PCR mixture included 0.5 μM primers,
200 μM deoxynucleotides triphosphate, Fusion HF Buffer, 0.4 U of Phusion Hot Start
DNA polymerase (Finnzymes) and 3% of dimethyl sulfoxide in a final volume of 20 μl.
The amplification was performed using the following cycle conditions: initial
denaturation at 98 °C for 1 min, followed by 30 cycles of 10 s at 94 °C (denaturation),
45 s at 58 °C (annealing) and 30 s at 72 °C (elongation). The housekeeping gene ACTB
was used as reaction and loading control and were simultaneously amplified with the
target genes. Data were acquired using a GelDoc 2000 instrument (BioRad) and were
elaborated using the Quantity One software (BioRad). Primer sequences were
summarized in Table 1 shown below.
Materials and Methods
42
Table 1: Sequence of primer
Gene Forward primer Reverse primer
SAT-I 5’-GGGAGTAATAGCATGGGCAACCAT-3’ 5’-CAGCTCTCAGAGTTAGAGTTGCATT-3’
ACTB 5’-CGACAGGATGCAGAAGGAG-3’ 5’-ACATCTGCTGGAAGGTGGA-3’
Administration of exogenous gangliosides
A2780 confluent monolayer cells were washed with serum-free culture medium and
then incubated in the presence of 50 μM GM3, GM2, GM1 or GD1a in serum-free
medium for up to 48 hours [215]. The following experiments were conducted after the
treatment.
Glucosylceramide synthase inhibition
To study the effects of ganglioside synthesis inhibition, the GlcCer synthase inhibitor
D-PDMP (D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol) was used
(221). As negative control, cells were treated with the inactive stereoisomer L-PDMP
under the same experimental conditions. D- and L-PDMP were kindly provided by Dr.
Jin-ichi Inokuchi (Tohoku Pharmaceutical University, Japan). The compounds were
dissolved in distilled water at a concentration of 4 mM. The stock solution was stored at
-20 °C and diluted with cell culture medium to a final concentration of 10 μM or 20 μM
just before use. A2780/HPR and A2780/SAT-I cells were seeded and cultured in the
presence of D- or L-PDMP for 48 h. The effects of PDMP on ganglioside synthesis
were detected by analyzing the lipid composition of the treated cells.
In vitro cell motility
Determination of in vitro cell motility by wound healing assay
Cells grown in 100-mm culture dishes as confluent monolayers were mechanically
scratched using a 200-μl pipette tip or a rubber policeman. Cells were washed with
complete culture medium and then incubated in the presence of complete culture
medium for different times allowing wound healing. Phase contrast images of the
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wounds were taken in nine random fields immediately after wounding (time 0) and after
24 and 48 hours, and wound width was measured. Each experimental point was in
duplicate, and data were expressed as the mean values ± S.D. of three independent
experiments.
Determination of in vitro cell motility by Phagokinetic Gold Sol Assay
Phagokinetic assays with gold colloid-coated plates were performed as described (224).
Briefly, 24-mm coverslips were coated with 1% bovine serum albumin (BSA) (Sigma-
Aldrich) and then immersed in the colloidal gold solution (225,226). Two-thousand
cells were seeded on the gold colloid-coated coverslips and incubated at 37°C. Images
of the phagokinetic tracks were taken after different times by the use of a phase contrast
microscope. The tracks of at least 50 cells were videocaptured and the areas cleared
from gold colloid by cell phagocytosis, representing the migration response, were
quantified by the use of Image J software.
Protein analysis
Treatment of cell cultures with [1-3H]sphingosine
To qualitatively and quantitatively analyze the cellular ganglioside expression pattern
with high sensitivity, A2780/SAT-I cells were grown in 100 mm diameter Petri dishes
and after 24 hours they were incubated with [1-3H] sphingosine that was dissolved in
complete culture medium. [1-3H] sphingosine was administered at a concentration of 3
× 10-8 M, which is under the concentration known to cause biological effects. In these
experimental conditions the [1-3H] sphingosine administration does not change the
viability and the morphology, observed with optical microscopy, of these cells. To
perform a metabolic labeling of the sphingolipids at the steady-state, the cells were
incubated with the [1-3H] sphingosine containing medium for 2 hours (pulse). After the
pulse, the medium was replaced with fresh medium without radioactive sphingosine,
and cells were further incubated for up to 2 days (chase). In these experimental
conditions the cultured cells efficiently incorporate the radioactive sphingosine that is
then quickly acylated to ceramide, which serves as a precursor for all sphingolipids,
included the complex ones. With this method of labeling, every sphingolipid (including
ceramide, SM, neutral glycolipids, and gangliosides) and phospholipid (obtained by
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recycling of radioactive ethanolamine formed in the catabolism of [1-3H] sphingosine)
were radioactively labeled (227-229).
Preparation of DRM fractions by sucrose gradient centrifugation
Cells were subjected to homogenization and to ultracentrifugation on discontinuous
sucrose gradient, as previously described (227). Briefly, cells were harvested, lysed in
1% Triton X-100 in TNEV (10 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, 5 mM
EDTA) in the presence of 1 mM Na3VO4, 1 mM PMSF, and 75 mU/ml aprotinin, and
Dounce homogenized (10 strokes, tight). Cell lysate was centrifugated for 5 min at 1300
× g to remove nuclei and cellular debris. The postnuclear supernatant (PNS) was mixed
with an equal volume of 85% sucrose (w/v) in TNEV, placed at the bottom of a
discontinuous sucrose gradient (30% - 5%), and centrifugated for 17 h at 200,000 g at 4
°C with ultra-centrifuge Beckman Coulter optima L-90K. After ultracentrifugation,
eleven fractions were collected starting from the top of the tube. The protein levels and
lipid distribution were analyzed individually in each fraction. Moreover, equal amounts
of the low-density fractions 4, 5 and 6 were put together to obtain the DRM fraction,
whereas equal amounts of the high-density fractions 9, 10 and 11 were put together to
obtain the HD fraction. The fractions 7 and 8 were also put together to obtain the
intermediate fraction. The entire procedure was performed at 0-4°C in the ice
immersion. For investigating the metabolism of sphingolipids and phospholipids, cells
were previously labeled with [1-3H]sphingosine.
Caveolin-1 immunoprecipitation
A2780/SAT-I 4T cells were grown in 100 mm diameter Petri dishes. The following day
20 μM D- or L-PDMP were added to the culture medium. A group of cells was left
untreated and used as control. The cells were treated for 48 hours with the
glucosylceramide synthase inhibitor before proceeding with the experiment.
After the treatment, A2780/SAT-I 4T cells were washed twice with phosphate buffered
saline (PBS) 1x containing 1 mM Na3VO4, and scraped in PBS-EDTA 0.02% containing
1 mM Na3VO4. The cell suspension was then centrifugated at 244 g for 10 minutes at 4
°C, and the cells were resuspended in lysis buffer (1% Triton X-100 (w/v), 50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 2 mM NaF, 1 mM EDTA, 1 mM EGTA) containing a
mixture of protease inhibitors (1 mM Na3VO4, 1 mM PMSF, 75 milliunits/ml aprotinin)
and homogenized with a Dounce homogenizer (10 strokes, tight). Cell lysate was
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centrifugated at 1300 g for 5 minutes to remove nuclei and cellular debris. The
postnuclear supernatant (PNS) concentration was determined by DC assay and adjusted
to a final concentration of 1.5 mg/ml. Aliquotes (1.2 mg in 800 μl) of the PNS were pre-
cleared for non-specific binding by adding 80 μl of protein A-coupled magnetic beads
(Dynabeads, Invitrogen), previously washed three times with PBS 1x. Non-specifically
bound material was eluted in 50 μl of Laemmli buffer 2x (1x: 62.5 mM Tris-HCl pH 6.8,
2% SDS, 5% 2-mercaptoethanol, 0.01% Bromophenol blue, 10% glycerol) and used a
negative control. After pre-clearing, 3 μg of anti-Cav-1 (BD Transduction Laboratories)
or 3 μg of normal rabbit IgG (as a negative control) added to the supernatant and the
mixtures were stirred overnight at 4°C, thus allowing the immunocomplex formation.
Immunoprecipitates were recovered by adding 80 μl of protein A-coupled magnetic
beads, previously washed with PBS 1x, and by stirring the mixtures for 4 hours at 4°C.
Beads were recovered by centrifugation at 1300 g for 5 minutes at 4°C, and the
supernatant was collected as SNIP (supernatant after immunoprecipitation). Bound
proteins were eluted in 50 μl of Laemmli buffer 2x and kept as IP (immunoprecipitate).
The samples were analyzed by western blotting using specific antibodies. The
conditions used for this immunoprecipitation experiment consent to recover not only the
target protein, but also the proteins associated to the target allowing to determine which
proteins interact with the targeted molecule.
Protein quantification
The protein quantification was performed through DC assay (Bio-rad). This
colorimetric assay, similar to the Lowry assay, allows to quantify proteins in presence
of different concentrations of detergents. The assay is based on the reaction of protein
with an alkaline copper tartrate solution and Folin reagent. In alkaline conditions, Cu2+
ions form coordination complexes with -NH groups of amino acids; these complexes
interacting with the Folin reagent, determine its reduction. Amino acids, like tyrosine
and tryptophan, bind the Folin reagent forming blue coloured complexes that can be
detected by measuring the absorbance at 750 nm with the spectrophotometer.
The assay was performed in a 96 well plate following the protocol supplied with the
Bio-rad DC assay kit. The samples diluted in lysis buffer (1% Triton X-100 (w/v), 50
mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM NaF, 1 mM EDTA, 1 mM EGTA, 1 mM
Na3VO4, 1 mM PMSF, 75 milliunits/ml aprotinin) were analyzed in triple, like the
protein standard, bovine serum albumin (BSA), at different concentrations. 25 μl of
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reagent A and 200 μl of reagent B, both supplied with the kit, were added to each well.
After 15 minutes of incubation, the absorbance at 750 nm was measured with the
spectrophotometer. The samples reading were compared with the ones of the standard.
The assay is linear between 1.5 and 7.5 μg/μl of protein amount.
Polyacrilamide gel electrophoresis
The samples were analyzed using electrophoresis on a polyacrilamide gel with
denaturing conditions, a technique which allows to separate proteins previously
denatured at a high temperature and in the presence of denaturing and reducing agents.
The samples were resuspended in Laemmli buffer (1x: 62.5 mM Tris-HCl pH 6.8, 2%
SDS, 5% 2-mercaptoethanol, 0.01% Bromophenol blue, 10% glycerol) and boiled for 5
minutes at 100 °C before being analyzed. This buffer contains sodium dodecyl sulfate
(SDS), an anionic detergent which binds most proteins in amounts roughly proportional
to the molecular weight of the protein, about one molecule of SDS for every two amino
acid residues. The bound SDS contributes a large net negative charge, rendering the
intrinsic charge of the protein insignificant and conferring on each protein a similar
charge-to-mass ratio. In addition, the native conformation of a protein is altered when
SDS is bound, and most protein assume a similar shape. The presence of β-
mercaptoethanol, which breaks disulfide bonds, and the high temperature also
contribute to the loss of the native conformation of a protein. Electrophoresis in these
conditions therefore separates proteins almost exclusively on the basis of the molecular
weight, with smaller polypeptides migrating more rapidly.
The electrophoresis run was performed using a Miniprotean II unit, produced by Bio-
rad. To obtain optimal resolution, a stacking gel is polymerized on top of the resolving
gel. The stacking gel has a lower concentration of acrylamide, which determines larger
pore size, lower pH and a different ionic content. This allows the proteins in a lane to be
concentrated into a tight band before entering the running or resolving gel and produces
a gel with tighter or better separated protein bands. After migrating through the stacking
gel, the proteins enter the running gel where they separate on the basis of their
molecular weight. A solution of 25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3 was
used as running buffer. The proteins were separated using 10% polyacrylamide gels.
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Western blotting
After electrophoresis separation, proteins were transferred to polyvinylidene difluoride
(PVDF) membranes, at 200 mA for 3 hours at 4°C with a wet blotting (Mini Transblot
Biorad). The transfer buffer used is Blotting buffer 1x (25 mM Tris-HCl, 192 mM
glycine, 15 % methanol, pH 8.0-8.5). The membrane used for the protein transfer has a
nonpolar nature therefore, before use, the PVDF membranes were wet in 100%
methanol, to which increasing amounts of water were added until 100% of water and
then equilibrated in blotting buffer 1x for at least 10 minutes. After the transfer, the
PVDF membranes were immunoblotted using antibodies anti-caveolin-1 (BD
Transduction Laboratories), anti c-Src (Cell Signaling), anti-integrin α5 (BD
Transduction Laboratories), and anti-integrin β1 (BD Transduction Laboratories).
Briefly, after the transfer the membrane was incubated in 5% milk defatted in TBS-T
0.05% (1 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween) to block the aspecific
binding sites of the membrane. The membrane was then washed three times with TBS-T
0.05% and incubated with a specific antibody (primary antibody) either overnight at
4°C or 1 hour at room temperature, depending on the antibody used. The primary
antibody was diluted in a solution of TBS-T 0.05% containing 1% bovine serum
albumin (BSA). The membrane was washed again with TBS-T 0.05% for four times, to
get rid of the antibody excess, before being incubated with the secondary antibody, a
rabbit or mouse anti-IgG, depending on the origin of the primary antibody, conjugated
with horseradish peroxidase (HPR) at room temperature for 45 minutes. The membrane
was then washed again for six times and the peroxidase activity was assessed through
incubation with a non-radioactive light emitting substrate for the detection of
immobilized specific antigens conjugated with horseradish peroxidase-linked antibodies
(LiteAbLot Plus, Euroclone) for 2 minutes. The luminescent compound generated
following the reaction can be detected through exposition to a photographic film
(Kodak BioMax MR Film, Sigma-Aldrich). The data acquisition was performed using a
GS-700 Imaging Densitometer and acquired blots were elaborated using the Quantity
One software (BioRad). Each experimental point was performed in triplicate, and data
were expressed as the mean values ± S.D. of three independent experiments.
In some cases the membrane used for the Western Blotting underwent stripping to
completely remove the protein-bounded antibodies and analyze the samples with other
antibodies.
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The membrane was incubated in a buffer containing Tris-HCl 62.5 mM, 2-
mercaptoethanol 100 mM, 2% SDS pH 6.7 for 30 minutes at 50° C in agitation. The
stripped membrane was then abundantly washed with TBS-T 0.05% until complete
elimination of the stripping buffer. The membrane was then used in a new procedure of
immunoblotting.
Table 2. Antibodies used for western blotting
Protein
Primary antibody Secondary
antibody
(Incubation)Type Blocking Incubation
Caveolin 1 Polyclonal,anti-rabbit
Overnight,
4°C 1 h, RT 45 min, RT
c-Src Monoclonal,anti-rabbit
Overnight,
4°C 1 h, RT 45 min, RT
Integrin α5 Monoclonal,anti-mouse 2 h, RT
Overnight,
4°C 45 min, RT
Integrin β1 Monoclonal,anti-mouse 2 h, RT
Overnight,
4°C 45 min, RT
Lipid analysis
DRM fractions were prepared as described above. Lipids in PNS and in sucrose
gradient fractions were extracted with chloroform/methanol/water 2:1:0.1 by volume (in
the case of gradient fractions, water was omitted), and subjected to a two-phase
partitioning, aqueous phase and organic phase. Then lipids in the aqueous phase or in
organic phase were dried under N2, and dissolved in the same volume of
cholesterol/methanol, 2:1 by volume.
To determine the endogenous ganglioside content, the aqueous phase lipids were
analyzed by HPTLC, using as solvent systems chloroform/methanol, 9:1 and
chloroform/methanol/0.2% aqueous CaCl2, 55:45:10 (spray reagent: Ehrlich) by volume,
successively. In order to determine cholesterol, after methylation the organic phase
lipids were analyzed by HPTLC, using as solvent systems Hexan:Ethyl acetate, 3:2
(spray reagent: Anisaldehyde) by volume. The endogenous phospholipid content in the
organic phase was also analyzed by HPTLC, using as solvent systems
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chloroform/Methanol/Acetic acid/H2O, 30:20:2:1 (spray reagent: 15% H2SO4 in 1-
Butanol) by volume. On HPTLC were loaded the same volume of each fraction. Data are
expressed as nmol of lipids per mg protein.
ECM adhesion
Cell adhesion to fibronectin
Cell adhesion to defined matrix components was accomplished as previously described
(230). In brief, flat-bottomed, polystyrene, 24-well plates were incubated overnight at 4
°C with 40 μg fibronectin in 250 μl of PBS (160 μg/ml) per well. Human fibronectin
(Sigma) was used as substrates. Plates were washed with 500 μl of 1% bovine serum
albumin (BSA) in PBS twice to remove unbound fibronectin and also to block any
remaining reactive surfaces. Nonspecific cellular binding was determined by using
wells coated only with 1% BSA. After the wells were washed with PBS, 1×105 cells per
well in 250 μl of RPMI-1640 medium was plated, and the cells were incubated at 37 °C
for 30 min for attachment to the fibronectin substrate. The cell adhesion was evaluated
measuring the mitochondrial oxidative activity through MTT reduction assay. The MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), yellow and soluble, is
incorporated from the cell and reduced by the mitochondrial succinate dehydrogenase
with the formation of purple formazan crystals, insoluble in aqueous solution. After
nonadherent cells were washed off, 25 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (5 mg/ml) was added to the culture and incubated
at 37 °C for 3 h, to allow the compound reduction, and then 250 μl of soluble solution
(0.1 M HCl in 10% SDS (w/v) solution) was added and mixed completely, and then was
incubated at 37 °C overnight, to dissolve the formazan crystals. Optical density
(absorbance at 570 nm minus that at 650 nm) was measured to evaluate cells attached to
the substrate.
ECM adhesion assay
Cell adhesion to different extracellular matrix proteins was assessed using an ECM Cell
Adhesion Array Kit (ECM540, Millipore), which utilizes a colorimetric detection
format. The kit contains a 96-well plate consisting of 12 × 8-well removable strips.
Seven wells of each strip are pre-coated with a different ECM protein (Collagen type I,
collagen type II, collagen type IV, fibronectin, laminin, vitronectin, and tenascin), while
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one well is coated with bovine serum albumin (BSA). The BSA-coated well is used to
determine non-specific cell adhesion. The cell adhesion was tested in different
conditions (wild type cells and 4T untreated cells; three replicates for each condition)
following the protocol supplied with the adhesion kit.
A2780 wild type and A2780/SAT-I 4T cells were cultured in 60 mm Petri dishes. The
cells were collected and counted, and the cell suspension was centrifugated at 1100 rpm
for 5 minutes. The supernatant was discarded and the cells were resuspended in the
assay buffer supplied with the kit. 1.6 x 104 cells were added to each well of the ECM
array plate and incubated for 10 minutes at 37 °C with 5% CO2. After incubation, the
wells were washed thrice with assay buffer before adding 100 μl of cell stain solution
and incubating the plate for 5 minutes at room temperature. The stain was then removed
and the wells were washed with deionized water for 5 times. The wells were allowed to
dry for a few minutes, then 100 μl of extraction buffer, a solution containing alcohol,
were added to each well. The strips were incubated at room temperature on an orbital
shaker until the cell-bound stain was completely solubilized (about 10 minutes).
Absorbance at 570 nm was measured with a spectrophotometer.
Determination of the linearity range of the crystal violet dye
The cell stain solution used for the ECM adhesion assay, supplied with the ECM Cell
Adhesion Array Kit (ECM540, Millipore), contains crystal violet, a dye that colors
intact living cells. To verify the linearity range of the dye, A2780/SAT-I 4T monoclonal
cells were grown in 60 mm diameter Petri dishes until they reached 90 % of confluence.
The cells were collected, counted and resupended in array buffer. Different amounts of
cells were then seeded at different concentrations (0, 100, 1 x 104 - 3 x 104 cells/well;
three replicates for each concentration) on a 96-well plate and incubated at 37 °C, 5%
CO2 for 2 hours. The wells were then washed three times with the assay buffer and 100
μl of cell stain solution were added to each well. After 5 minutes of incubation at room
temperature, the stain was removed and the wells were washed with deionized water for
5 times. The wells were allowed to dry for a few minutes, then 100 μl of extraction
buffer were added to each well. The strips were incubated at room temperature on an
orbital shaker until the cell bound stain was completely solubilized (about 10 minutes).
Absorbance at 570 nm was measured with a spectrophotometer.
siRNA transfection
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A2780/HPR or A2780/SAT-I cells were plated in 6-well plates or 100-mm dishes and,
when grown at 50% confluence, were transfected with CAV1 siRNA (Qiagen, cat. no.
SI00299635) or with scrambled siRNA duplexes (Qiagen, All stars negative control siRNA
cat. no. 1027280) as transfection control. The optimal condition for the transfection was 32
nM siRNA in Opti-MEM with Lipofectamine 2000 (1%, v/v) (Invitrogen), following the
protocol provided by the manufacturer. Fresh medium was added 24 h after transfection,
and experiments were conducted for different times up to 72 h. In the case of the cell
adhesion assay, cells were pre-treated with siRNA for 48 h before the assay.
Statistical analysis
Experiments were run in triplicate, unless otherwise stated. Data are expressed as mean
value ± S.D. and were analyzed by oneway analysis of variance followed by Student-
Neuman-Keul’s test. p-values are indicated in the legend of each figure.
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GM3 synthase overexpression in A2780 cells
In order to investigate the role of gangliosides in the regulation of tumor phenotype , we
stably overexpressed the cDNA enconding sialyltransferase-I (GM3 synthase or SAT-I)
in A2780 human ovarian carcinoma cells. The sialyltransferase-I is a key enzyme which
controls the sialylation step leading to the synthesis of ganglioside GM3 from
lactosylceramide (LacCer).
As shown in Figure 8, the SAT-I mRNA levels (Panel A) were markedly up-regulated
in the three SAT-I transfected clones (4T, 28T and 31T) with respect to wild type and
mock transfected A2780 cells. Consistently, cellular ganglioside content was higher in
SAT-I tranfectants (Figure 8, Panel B). The increase in the gangliosides content in SAT-
I transfectants was due to higher levels of GM3, GM2, and GD1a. The mRNA level of
GM3 synthase and gangliosides content in fenretinide-resistant A2780/HPR cells were
also detected. Both of the mRNA level of SAT-I and gangliosides content were much
higher compared to A2780 wild type cell.
A
B
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Figure 8. SAT-I expression and glycosphingolipid composition in A2780
variants. Panel A, SAT-I mRNA levels were assessed in wild type A2780
cells, A2780 transfectants (one mock and 3 SAT-I-transfected clones, 4T,
28T, and 31T) and A2780/HPR cells by reverse transcriptase PCR. β-Actin
mRNA expression was measured as an internal control. Patterns are
representative of those obtained in three different experiments. Panel B, cell
lipids were metabolically labeled with [1-3H]sphingosine as described in
Materials and methods. Lipids were extracted with
chloroform/methanol/water. The total lipid extracts and the partitioned
aqueous and organic phase lipids were separated by HPTLC. Radioactive
lipids were visualized by digital autoradiography. The radioactivity
associated with each lipid was determined with specific Beta-Vision
software. Data are expressed as percentage of the total radioactivity
incorporated into sphingolipids and are the means ± S.D. of three different
experiments. *P < 0.01 versus A2780. **P < 0.05 versus A2780.
Elevated cellular ganglioside levels reduced in vitro motility of A2780
cells
We investigated the effect of increased GM3 synthase expression levels on A2780 in
vitro motility (Figure 9,A). Overexpression of GM3 synthase did not significantly affect
the growth rate of A2780 cells (data not shown). On the other hand, wound healing
assay revealed that the in vitro motility of all SAT-I transfectants (4T, 28T and 31T)
was strongly reduced when compared with wild type or mock-transfected A2780 cells.
A2780/HPR cells which endogenously express high levels of GM3 synthase, also
showed a lower in vitro motility than A2780 cells. Above all, high levels of GM3
synthase expression were sufficient to negatively regulate the in vitro motility of A2780
human ovarian carcinoma cells without influencing the cell growth and this may be due
to the consequent increase of cellular ganglioside levels.
To validate and substantiate the hypothesis that changes in the ganglioside patterns
consequent to SAT-I overexpression could be responsible for the reduced motility in
A2780 cells, we incubated A2780 cells in the presence of exogenous gangliosides under
experimental conditions that allowed us to increase by 3- to 20-fold the trypsin-stable
cellular content of the administered gangliosides (data not shown). Under these
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conditions, we observed that the exogenous administration of GM3 and GM2, both
natural components of A2780 cells, and of GM1, virtually absent from these cells,
effectively reduced the in vitro motility of these cells (Figure 9,B). On the other hand,
GD1a, present as minor ganglioside in A2780 cells but representing 15% - 22% of total
gangliosides of SAT-I-transfected clones, had no effect on A2780 cell motility.
Figure 9. Effect of elevated SAT-I expression and exogenous
administration of gangliosides on in vitro motility of A2780 cells. Panel
A, in vitro motility of A2780 cells, A2780 transfected with the empty
expression vector (mock) or the vector containing the SAT-1 cDNA (clones
4T, 28T and 31T), and A2780/HPR cells has been assessed by a wound
healing assay as described in Materials and Methods. Confluent monolayers
were wounded with a rubber policeman, the wound width has been
measured at 0, 24 and 48 hours. Data are expressed in mm, and are the
means ± S.D. of three different experiments. *, P < 0.01 versus time-
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matched A2780. Panel B, A2780 confluent monolayers were wounded and
incubated in serum-free medium in the presence of vehicle(control) or of 50
μM GM3, GM2, GM1 or GD1a for up to 48 hours. The wound width has
been measured at 0, 24 and 48 hours. Data are expressed in mm, and are the
means ± S.D. of three different experiments. *, P < 0.01 versus time-
matched control.
Elevated cellular ganglioside levels increased in vitro adhesion of
A2780 cells to fibronectin
The α5β1 integrin, which is the most expressed integrin heterodimer in A2780 cells, has
been reported to bind to the extracellular matrix components fibronectin, type I collagen,
and laminin (231). The ability of the SAT-I transfected monoclonal cells to adhere to
fibronectin, a major ligand of α5β1 integrin, was compared with that of A2780 wild-
type cells and A2780/HPR cells (Figure 10,A). Adhesion to bovine serum albumin
(BSA) was also examined as a non α5β1 integrin-mediated adhesion control. Adhesion
was examined after a 30 minutes incubation of the cells on the coated wells using a
MTT reduction assay as described in the Materials and Methods. After 30 minutes of
incubation, there was nearly no cell binding to BSA coated wells. On the fibronectin
coated wells, both SAT-I transfected cells and A2780/HPR cells had a strong adhesive
ability compared to A2780 wild-type cells. Since the cell adhesive ability usually has a
reversed behavior of in vitro cell motility, this data is consistent with the motility results
observed above. GM3 synthase overexpression resulted in an increase of cell adhesion,
and also in a decrease of in vitro cell motility, suggesting a possible role of gangliosides
in controlling integrin-mediated cell motility and adhesion.
To further verify if the content of gangliosides was related to the cell adhesion,
exogenous gangliosides were administered to A2780 cells. Briefly, A2780 cells were
pre-treated with gangliosides for 48 hours as described in the Materials and Methods.
The cell adhesion assay was conducted by using fibronectin-coated 24-well plates and
adhesion was measured using an MTT reduction assay as described in Materials and
Methods. As shown in figure 10, there was no significant difference of the tendency of
binding to BSA-coated wells among control, gangliosides GM3- and GD1a-treated
A2780 cells (Panel B). However the cells treated with gangliosides GM3, attached more
strongly to the fibronectin-coated wells, compared to control and to cells treated with
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GD1a. Since exogenous administration of ganglioside GM3 significantly reduced the
A2780 cell motility, but GD1a did not, we supposed that in A2780 human ovarian
carcinoma cells, high levels of ganglioside GM3 resulted in a relatively high adhesion,
and thus in reduced in vitro cell motility. Notably, fibronectin, as an important
extracellular matrix protein, has a specific affinity for integrin α5β1, which is the main
type of integrin expressed in A2780 cells, suggesting that integrin α5β1 is involved in
GM3-mediated regulation of in vitro motility and adhesion in A2780 cell.
Figure 10. Effect of elevated SAT-I expression and exogenous administration of
gangliosides on in vitro adihesion of A2780 cells. Human fibronectin and bovine
serum albumin (BSA) were coated in 24-well plate at 4 °C overnight. On the other
day, the plate was washed with PBS before use. Panel A, 1×105 of A2780,
A2780/HPR and A2780/SAT-I cells were respectively plated in each well and
incubated at 37°C for 30 min allowing cell adhesion. Then non-adherent cells were
washed off. MTT assay was performed to evaluated the number of adherent cells as
described in Materials and methods. Data are the means ± S.D. of three different
experiments. *, P < 0.05 versus A2780 cells. Panel B, A2780 cell confluent
monolayers were pre-treated with vehicle (control) or 50 μM GM3 or GD1a in serum-
free culture medium for 48 hours. After that, cell adhesion was evaluated following
the procedure as described in Materials and methods. Data are the means ± S.D. of
three different experiments. *, P < 0.05 versus control, cells treated with vehicle only.
Gangliosides depletion reduced in vitro motility and increased adhesion
of A2780/SAT-I cells
Results
58
High expression levels of GM3 synthase, leading to high cellular gangliosides content,
in A2780/SAT-I-transfected cells were associated with a reduction of in vitro cell
motility and an increased cell adhesion. Consistently, treatment with exogenous
gangliosides was able to reduce the motility and increase the adhesion of low GM3
synthase A2780 cells, suggesting a role of gangliosides in controlling the motility and
adhesion of these cells. To conform this hypothesis, we assessed the effect of the
pharmacological manipulation of ganglioside levels on the in vitro motility and
adhesion of A2780/SAT-I cells. Treatment of A2780/SAT-I cells with the specific
GlcCer synthase inhibitor D-PDMP strongly reduced gangliosides content after 2 days
(Figure 11,A). L-PDMP (the ineffective isomer, used as a negative control) had no
effect on glycosphingolipid levels in A2780/SAT-I cells, as expected. Both of L- and D-
PDMP did not alter the cellular levels of ceramide and sphingomyelin (SM) in
A2780/SAT-I cells. Thus, D-PDMP treatment can be an appropriate tool to study the
role of gangliosides in A2780 cells.
Treatment with L- or D-PDMP was not toxic; however, it slightly reduced A2780/SAT-
I cell proliferation in a dose-dependent manner (data not shown). Since PDMP
treatment influenced cell number, phagokinetic gold sol assay (PGSA) was carried out
to determine in vitro cell motility instead of wound healing assay. Phagokinetic gold sol
assay is highly independent from the cell number and analyzes the migration behavior
of the single cell. The assay is based on the principle that migrating cells ingest, push to
one side, or collect small particles on their dorsal surface in their path. At least fifty of
single cells were analyzed for each situation. Treatment with D-PDMP, but not with L-
PDMP, was able to significantly increase the motility of A2780/SAT-I cells (Figure
11,B). Above all, these results further suggest a role for gangliosides in the regulation of
A2780 human ovarian cancer cell motility, demonstrating that the high content of
gangliosides resulted in low cell in vitro motility; while on the contrary, low content of
gangliosides resulted in high cell motility.
Since cell motility is tightly correlated with the adhesive ability, we supposed that
PDMP treatment may also affect cell adhesion. To confirm this hypothesis, we assessed
the effect of the pharmacological manipulation of ganglioside levels on the in vitro
adhesion of A2780/SAT-I transfected cells. A2780/SAT-I 4T monoclonal cells were
pretreated with PDMP for 48 hours to inhibit the endogenous gangliosides synthesis.
The treatment with L- or D-PDMP did not shown toxicity at the concentration used for
this experiment. The adhesive ability of these cells was analyzed following the cell
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adhesion assay protocol as described in Materials and Methods. D-PDMP treatment
significantly reduced the cell adhesion to fibronectin, while treatment with L-PDMP,
the inactive stereoisomer used as a negative control, had no effect on cell adhesion,
which was similar to the untreated control (Figure 11,C). The correlation between high
GM3 content and decreased motility/increased adhesion, and the results obtained upon
ganglioside depletion, indicate that gangliosides, especially GM3, might play an
important role in modulating both cell motility and adhesion in A2780 cells. The
mechanism of this regulation and if other molecules also take part in this procedure
though need to be further investigated.
Figure 11. Effects of PDMP treatment on sphingolipids composition
and on in vitro cell motility and adhesion of A2780/SAT-I cells.
A2780/SAT-I 4T cells were treated with the specific glucosylceramide
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synthase inhibitor D-PDMP to achieve sphingolipid depletion. The
ineffective stereoisomer L-PDMP has been used as a negative control.
Panel A, Sphingolipid patterns of A2780/SAT-I cells untreated (control),
treated with 20μM L-PDMP or D-PDMP for 48 hours. Cell lipids were
extracted with chloroform/methanol/water, 2:1:0.1 by volume, subjected to
a two-phase partitioning. Organic phase (left panel) and Aqueous phase
(right panel) lipids were analyzed by HPTLC, using
chloroform/methanol/0.2% aqueous CaCl2, 50:42:11 by volume (spray
reagent, p-dimethylaminobenzaldehyde) for aqueous phases; and
chloroform/methanol/water, 55:20:3 by volume (spray reagent, 15% H2SO4
in 1-butanol) for organic phases as solvent system respectively. The
equivalent to 1 mg of cell proteins were loaded on each lane. Panel B, effect
of PDMP on in vitro cell motility of A2780/SAT cells. A2780/SAT-I 4T
cells were treated with 10 μM of L- or D-PDMP for 48 hours. Phagokinetic
gold sol assay (PGSA) was performed as described in Materials and
Methods. The L- or D-PDMP was matained in the medium for the whole
duration of the assay. Phase-contrast microscopy images of the areas of the
tracks cleared by the cells (left panel shows representative images for each
data set) have been recorded at time 0 and after 48 hours. Average track
areas (means ±S.D. of 50 measurements) normalized for the different cell
size are reported in the bar graph (right panel). Panel C, effects of PDMP
treatment on in vitro adhesion of A2780/SAT-I cells has been assessed by
cell adhesion assay as described in Materials and methods. Data are the
means ± S.D. of three different experiments. *, P < 0.05 versus control. #, P
< 0.05 versus L-PDMP-treated cells.
In vitro cell adhesion to ECM proteins of A2780 and A2780/SAT-I cells
The principal receptors on animal cells for binding most extracellular matrix proteins
are the integrins, a family of heterodimeric transmembrane receptors consisting of
noncovalently bound α and β subunits. Most integrins recognize several ECM proteins.
Conversely, individual matrix proteins, such as fibronectin, laminins, collagens, and
vitronectin, bind to several integrins. For example at least eight types of integrin bind
fibronectin, and at least five types bind laminin. In A2780 cells, α5β1 integrin is the
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main type of integrin expressed and it has been hypothesized that this integrin
heterodimer might play a role in the regulation of GM3-mediated adhesion and motility.
However α5β1 integrin is not the only integrin receptor expressed by A2780 cells,
therefore other heterodimers might be involved in the regulation of adhesion and
motility. To verify if other integrin heterodimers could be involved in such processes,
we assessed the adhesive ability of A2780 cells to different extracellular matrix proteins.
To do so we performed an adhesion assay using an ECM cell adhesion array kit
(Millipore). This kit allows to test adhesion to 7 different ECM proteins, namely
collagen I, II, and IV, fibronectin, laminin, vitronectin, and tenascin. Bovine serum
albumin (BSA) was used to determine non-specific cell adhesion. The assay was
performed on A2780 wild type and A2780/SAT-I 4T cells as described in Materials and
Methods. Briefly, cells were collected, counted and seeded on the pre-coated wells.
After 10 minutes of incubation at 37 °C with 5% CO2, adhesion was measured using a
colorimetric assay. The cells were stained with a solution containing crystal violet,
which colors living cells, and, after washing the wells with deionized water, the cells
were incubated for 10 minutes at room temperature with an extraction solution
containing alcohol. Optical density was measured at 570 nm with a spectrophotometer.
The linearity range of the staining solution was verified by seeding different
concentration of cells on an uncoated 96-well plate and using the same colorimetric
detection method as described in Materials and Methods (data not shown).
As shown in figure 12, the two groups of cells showed a very weak adhesion to collagen
type I, II, and IV, and to tenascin suggesting that the integrin heterodimers involved in
the recognition of these proteins might be expressed only at a low level or not expressed
at all. On the other hand, the two groups of cells showed a slightly stronger adhesion to
laminin and vitronectin and an even higher adhesion to fibronectin. While the latter was
expected, since fibronectin has a specific affinity for α5β1 integrin and this heteodimer
is the most expressed in A2780 cells, the adhesion to laminin and vitronectin suggests
that integrin heterodimers such as αVβ1 and αVβ5, which bind vitronectin, or α3β1 and
α6β1, which bind laminin, might be involved in regulating the adhesion of A2780 cells.
The adhesion assay also allowed us to compare A2780 wild type cells and A2780/SAT-
I 4T cells. As expected, since it has been previously observed that cells with higher
ganglioside content also have higher adhesion, 4T cells showed a higher adhesion to
fibronectin and laminin. The involvement of integrin α5β1 in regulating the adhesion,
and motility, in A2780 wild type and A2780/SAT-I cells has been further investigated
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by analyzing the effect of PDMP treatment on this subunits distribution in gradient
fractions and by investigating the effect of the same treatment on the association
between these integrin subunits and other proteins, such as caveolin-1 and c-Src,
involved in the formation of a molecular complex involved in the regulation of cellular
processes.
Figure 12. In vitro cell adhesion to ECM proteins. A2780 wild type cells
were compared to A2780/SAT-I cells. The cell adhesion to collagen I, II,
and IV, fibronectin, laminin, tenascin and vitronectin was assessed using an
ECM cell adhesion array kit following the protocol described in Materials
and Methods.
Effects of PDMP treatment on lipids gradient distribution in
A2780/SAT-I cells
To address the mechanism underlying regulation of cell motility and adhesion by
gangliosides, the effect of ganglioside depletion by PDMP treatment on the association
of cellular components with detergent-resistant membrane fraction has been evaluated.
Firstly, the mass content for each lipid or lipid class has been determined
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colorimetrically as described in Materials and methods. As shown in Table I, lipid
levels were not affected by L-PDMP treatment. However, D-PDMP treatment
significantly reduced ganglioside content of A2780/SAT-I, leaving unaffected the total
phospholipids and cholesterol levels.
Table 1. Effect of PDMP treatment on the endogenous lipids content in
A2780 SAT-I-transfected clones. The mass content for each lipid or lipid
class has been determined colorimetrically as described in Materials and
methods. Data are expressed as nmol of lipid per mg of cell protein and are the
mean values ± S.D. of three different experiments. *, P < 0.05 versus control. #,
P < 0.05 versus L-PDMP-treated cells.
In order to analyze the effect of ganglioside depletion on the membrane
organization in these cells, we prepared a ganglioside- and caveolin-1 enriched
detergent resistant membrane (DRM) fraction from SAT-I transfected cells treated
with L- or D-PDMP. To do this, cells were lysed in the presence of Triton X-100
and subjected to discontinuous sucrose gradient centrifugation as described in
Materials and methods. As expected, the low density detergent resistant
membrane fraction (fractions 4, 5 and 6) was highly enriched in gangliosides.
Gangliosides levels were significantly reduced in all fractions in D-PDMP treated
cells (Figure 13,A). In addition, D-PDMP treatment determined a significant shift
of cholesterol from both DRM fraction and intermediate fraction (fractions 7 and
8) to high density fraction (Figure 13,B). This movement may be caused by the
dynamic of caveolin-1 (Figure 14,A); however, the mechanism is needed to be
explored. Glycerophospholipids content of each fraction was also analyzed by
HPTLC. The major amount of glycerophospholipids existed in high density
fraction (fractions 9, 10 and 11). Glycerophospholipids level were reduced in DRM
fraction and intermediate fraction, and increased in high density fraction by D-PDMP
treatment in this case (Figure 13,C).
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Figure 13. Effects of PDMP treatment on lipids distribution in
A2780/SAT-I cells. A2780/SAT-I 4T cells were treated with or without L-/D-
PDMP for 48 hours. The low-density fraction 4, 5 and 6 were pooled together
to obtain the DRM fraction, similarly the fraction 7 and 8 were pooled together
to obtain the intermediate fraction, whereas fractions 9, 10 and 11 were pooled
together to obtain the high density (HD) fraction. Lipids present in the pooled
fractions were extracted and analyzed as described under Materials and
methods. Panel A, effect of PDMP treatment on gangliosides distribution in
A2780/SAT-I transfected clones. Panel B, effect of PDMP treatment on
cholesterol distribution in A2780 SAT-I-transfected clones. Panel C, Effect of
PDMP treatment on phospholipids (PC and PE) distribution in A2780/SAT-I
transfected clones. Data are expressed as nmol of lipid per mg of cell protein
and are the means ± S.D. of three different experiments. *, P < 0.05 versus
control. #, P < 0.05 versus L-PDMP-treated cells.
Effects of PDMP treatment on protein gradient distribution in
A2780/SAT-I cells
Glycosphingolipids clusters at the cell surface membrane interact with functional
membrane proteins such as integrins, growth factor receptors, tetraspanins, and non-
receptor cytoplasmic protein kinases to form "glycosynaptic domains" controlling cell
growth, adhesion, and motility. Data previously obtained (5) suggests a role for
gangliosides in regulating tumor cell motility by affecting the function of a signaling
complex organized by caveolin-1, responsible for Src inactivation downstream to
integrin receptors, and imply that GM3 synthase is a key target for the regulation of cell
motility in human ovarian cancer. To analyze the effects of PDMP treatment on proteins
distribution, we prepared a ganglioside- and caveolin-1 enriched detergent resistant
membrane (DRM) fraction from SAT-I transfected cells treated with L- or D-PDMP
under the same experimental conditions as described above.
The distribution of caveolin-1, c-Src, integrin α5 and β1 along the gradient fractions
was analyzed by immunoblotting using specific antibodies. The DRM fraction, which is
enriched in sphingolipids (ceramide, GlcCer, sphingomyelin, and gangliosides), was
also highly enriched in caveolin-1, whereas integrin α5 was largely recovered in the
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high density fraction of the gradient, which also contains the major amount of
glycerophospholipids .
Treatment with D-PDMP, but not L-PDMP, was able to induce the shift of a significant
amount of caveolin-1 to intermediate fraction from both DRM fraction and high density
fraction (Figure 14,A) and the shift of a significant quantity of c-Src from the DRM
fraction to the intermediate fraction (Figure 14,B). In control cells, the amount of
integrin α5 and β1 associated with the DRM fraction was very low. After D-PDMP
treatment, integrin α5 moved from the high density fraction, to the DRM fraction and
intermediate fraction (Figure 15,B). D-PDMP treatment also determined a shift of
integrin β1 from the HD fraction to the intermediate fraction (Figure 15,A). Although
the distributions of caveolin-1, c-Src and integrin α5 were altered, the total expressions
of these proteins were not changed by PDMP treatment,.
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Figure 14. Effects of PDMP treatment on protein gradient distribution
in A2780/SAT-I cells. Cells were treated with 20 μM L- or D-PDMP for 48
hours. Cell gradient fractions were prepared by sucrose gradient
centrifugation after lysis in the presence of 1% Triton X-100 as described
under Materials and methods. The protein distribution was determined by
SDS-PAGE followed by Western blotting, using specific antibodies against
caveolin-1 (Panel A) and c-Src (Panel B). The relative quantities of each
protein in pooled DRM (fractions 4-6), Intermediate (fractions 7-8) and HD
(fractions 9-11) fractions were calculated by densitometry and were
expressed as percentage of total signal assessed in the histogram. The
loading volume is 1/100 of the total volume of each fraction. Patterns in the
lower part of each panel are representative of those obtained in three
independent experiments. *, p < 0.05 versus control. #, p < 0.05 versus L-
PDMP treated cells.
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Figure 15. Effects of PDMP treatment on protein gradient distribution
in A2780/SAT-I cells. Cells were treated with 20 μM L- or D-PDMP for 48
hours. Cell gradient fractions were prepared by sucrose gradient
centrifugation after lysis in the presence of 1% Triton X-100 as described
under Materials and methods. The protein distribution was determined by
SDS-PAGE followed by Western blotting, using specific antibodies against
integrin α5 (Panel A) and β1 (Panel B). The relative quantities of each
protein in pooled DRM (fractions 4-6), Intermediate (fractions 7-8) and HD
(fractions 9-11) fractions were calculated by densitometry and were
expressed as percentage of total signal assessed in the histogram. Patterns
are representative of those obtained in three independent experiments. Data
are the mean values ± S.D. of three different experiments. *, p < 0.05 versus
control. #, p < 0.05 versus L-PDMP treated cells.
Effect of PDMP treatment on the association of c-Src and integrin
receptor subunits with caveolin-1 in A2780/SAT-I cells
Caveolin-1, an integral membrane protein originally discovered as a main structural
component of caveolae, has the potential to act as a molecular organizer for ganglioside-
modulated signaling complexes. Several pieces of evidence indicate that caveolin-1 has
the ability to interact with several proteins involved in signal transduction and to
concentrate whole signaling modules in specialized plasma membrane areas, allowing
their functional regulation. Moreover caveolin-1 has a phosphorylation site, tyrosine 14,
which regulates Src activation. Caveolin-1 can also act as a membrane adapter, coupling
the integrin receptor to cytosolic Src-family kinases. Results described in the previous
section suggested that ganglioside depletion due to PDMP treatment, determines
caveolin-1 dissociation from gangliosides/caveolin complexes and the subsequent
association of caveolin-1 with integrin heterodimers. To confirm this hypothesis , we
performed immunoprecipitation experiments using a polyclonal anti-caveolin-1
antibody. A2780/SAT-I cells, which have a high content of gangliosides and an
elevated expression of caveolin-1, were pre-treated with 20 μM D- or L-PDMP for 48
hours before being collected and lysed in a solution containing Triton X-100. After a
step of centrifugation to remove nuclei and cellular debris, we proceeded with the
immunoprecipitation experiments as described in the Materials and Methods section.
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The presence of proteins such as caveolin-1, c-Src, integrin α5, and integrin β1 was
detected by immunoblotting with specific antibodies.
As shown in figure 16 and 17, the caveolin-1 protein levels in the treated and untreated
(control) cells were similar in the immunoprecipitate samples, indicating that the
immunoprecipitation efficiency, which is about 15%, was the same for the three groups
(Figure 16 and 17,A). The detection of c-Src, in the immunoprecipitate samples,
revealed similar levels of the protein kinase after treatment with either D- or L-PDMP
indicating that total levels of Src were not affected by the treatment (Figure 16,B).
Integrin α5 levels in the immunoprecipitate samples, on the other hand, increase
significantly after D-PDMP treatment, but not after the treatment with the inactive
stereoisomer (Figure 16,C and 17,B). This confirms the previous hypothesis suggesting
that D-PDMP treatment favors association of α5 with caveolin-1.
D-PDMP treatment also determines an increase of the percentage of integrin β1 in the
immunoprecipitate. In particular, there is an increase of the mature form of integrin β1
which suggests that this form is the one that combines with caveolin-1 and takes part in
the formation of the signaling complex. As shown in figure 16, the detection of β1 in
the immunoprecipitate of the three groups revealed the presence of three bands, whereas
only two bands are detected in the post nuclear surnatant. The lowest of the three bands
represents a partially glycosylated precursor form of β1 that resides in the endoplasmic
reticulum, while the middle one represents a further glycosylated form which is the
functional receptor. Regarding the highest band there are two hypotheses, it could an
aspecific band and thus not β1, or it might be a form of β1 which in the PNS is too low
to be detected and that is concentrated upon caveolin-1 immunoprecipitation, which
would mean that this form interacts preferentially with caveolin-1.
PDMP treatment did not affect the total levels of the protein analyzed, though D-PDMP
treatment, but not L-PDMP treatment, determined an increase in the levels of the
precursor form of integrin β1. This might be due to an aspecific effect of D-PDMP,
which could inhibit sialyltransferases involved in the process of maturation of integrin
β1.
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Figure 16. Effects of PDMP treatment on proteins associated with anti-
caveolin-1 immunoprecipitates in SAT-I transfected cells. A2780/4T cells
treated with D- or L-PDMP for 48 hours were collected and lysed in a solution
containing Triton X-100. Immunoprecipitation experiments were performed on
aliquots of the postnuclear surnatant (PNS) using a polyclonal anti-caveolin-1
antibody or normal rabbit IgG, as a negative control, as described in Materials and
methods. Patterns are representative of those obtained in three independent
experiments. Panel A, for the detection of caveolin-1 we loaded 1/10 of total
volume for Preclear samples, 1/580 of total volume for SNIP samples, and 1/35 of
total volume for IP samples. Panel B, for the detection of c-Src we loaded 1/10 of
total volume for Preclear samples, 1/580 of total volume for SNIP samples, and 1/8
of total volume for IP samples. Panel C, for the detection of integrin β1 we loaded
1/10 of total volume for Preclear samples, 1/580 of total volume for SNIP samples,
and 1/5 of total volume for IP samples. Panel D, for the detection of integrin α5 we
loaded 1/10 of total volume for Preclear samples, 1/580 of total volume for SNIP
samples, and 1/7 of total volume for IP samples.
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Figure 17. Effects of PDMP treatment on proteins associated with anti-
caveolin-1 immunoprecipitates in SAT-I transfected cells. The results
reported in figure 16 were quantitatively expressed in bar graphs. The
presence of caveolin-1, integrin α5 and integrin β1 in IP (anti-caveolin-1,
grey; anti-IgG, white) samples was revealed by western blotting with
specific antibodies. Data are expressed as percentage of total amount of each
protein in 1.2 mg PNS used for immunoprecipitation and are the means ±
S.D. of three different experiments. *, p < 0,05 versus control, untreated
cells. #, p < 0,05 versus L-PDMP treated cells.
Effect of Transient silencing of caveolin-1 on in vitro cell adhesion in
A2780/SAT-I cells
Since the levels of caveolin-1 expression were elevated in GM3 synthase overexpressed
A2780 cells, if caveolin-1 is involved in ganglioside GM3 mediated cell adhesion, is worthy
to be determined. Before that, if the transfection influences the cell proliferation levels need
to be checked. The cells were previously silenced with the siRNA targeting to caveolin-1
gene, and then cell proliferation levels were measured by MTT reduction assay as described
before. There was no difference between caveolin-1 silenced cells and scramble sequence
transfected cells in the rate of cell growth (data not shown).
According to this result, in vitro adhesion of caveolin-1 silencing could be assessed in
A2780/SAT-I cells. Caveolin-1 was silenced by siRNA transfection, and after 48 hours the
adhesion to fibronectin was performed as described in Materials and methods. The in vitro
adhesion of A2780/SAT-I transfected cells (Figure 18) was markedly higher in caveolin-1
silenced cells compared with scramble sequence transfected cells, suggesting a leading role
of caveolin-1 in the regulation of the cell adhesion signal in this cell model.
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Figure 18. Effects of caveolin-1 silencing on in vitro cell adhesion in
A2780/SAT-I cells. A2780/SAT-I-transfected A2780 cells have been treated
with siRNA targeting to CAV1 gene to reduce the expression of caveolin-1.
After 48 h treatment with scrambled siRNA or siRNA targeting to CAV1, cell
adhesion assay was performed as described in the materials and methods
section. Data are expressed in percentage respect to control cells treated with
scrambled siRNA, and are the means ± S.D. of three independent experiments.
*, p < 0.001 versus control, cells treated with scrambled siRNA.
Effects of exogenous administration of gangliosides on caveolin-1
expression and caveolin-1 phosphorylation level
Integrins connect the ECM to the actin cytoskeleton at special structures called focal
adhesions (FA) through a protein complex that includes vinculin, paxillin, tallin and α-
actinin (232). In addition, activation of integrins results in the recruitment of a number
of signalling molecules to FA, including focal adhesion kinase (FAK). Caveolin-1
protein is also found at FA, where most of the phosphorylated caveolin-1 pool resides
(104,233). Tyrosine phosphorylated Cav1 (pY14Cav1) appear to be essential for
maintaining a highly ordered state in the membranes around these adhesion complexes,
and this is likely to be due to the recruitment of membrane components that induce
order, such as cholesterol (234). Besides its structural role, caveolin-1 also participates
in active signalling at FA. In response to various stimuli, Src and other kinases
phosphorylate caveolin-1 on Tyr 14, and this phosphorylation is crucial for a number of
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functions attributed to caveolin-1. pY14Cav1 has also been reported to regulate Src
activity by recruting C-terminal Src kinase (Csk) to FA (235,236). Csk inhibits Src
activity by phosphorylating a conserved Tyr residue (243).
Since silencing of caveolin-1 by siRNA influenced the existence of pY14 Cav-1 on the
cell plasma membrane as published before (5), implied that maybe not only caveolin-1
was involved in gangliosides mediated cell signals, but also the caveolin-1
phosphorylation plays a certain role in this regulation. The tyrosine phosphorylation site
14 (pY14) of caveolin-1 is considered as the active form of caveolin-1. Moreover, it is
the major phosphorylation site of c-Src in vitro. Although its functional importance is
still unclear, the following study is trying to reveal the role of pY14 Cav-1 under
ganglisodies regulation. A2780 cells were exogenously administrated with gangliosides
under experiment condition. The cells were lysed for detecting caveolin-1 and pY14
Cav-1 expression. As shown in Figure 15, only ganglioside GM3 treatment slightly
increased caveolin-1 expression. Meanwhile, treatment of ganglioside GM3, GM2 and
GM1, but not GD1a, significantly increased the phosphorylation levels of caveolin-1
normalized by β -tubulin. mRNA levels of caveolin-1 were also analyzed by semi-
quantitative PCR and the results of mRNA levels showed the similar tendency as the
protein levels (data not shown). This data recalled us to the effect of gangliosides
treatment on the cell motility and adhesion in A2780 cells. It confirmed again that
caveolin-1 participated in gangliosides modulating cell signaling, and it suggested that
gangliosides mediated A2780 cell motility and adhesion through caveolin-1
phosphorylation.
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Figure 19. Effects of exogenous administration of gangliosides on caveolin-
1 expression and caveolin-1 phosphorylation level. A2780 cell confluent
monolayers were administrated with vehicle (control) or 50 μM of GM3, GM2,
GM1, or GD1a for up to 48 h. After that, cells were analyzed by Western
blotting detection using specific antibodies against caveolin-1 and Cav-1-pY14.
β-tubulin was simultaneously detected as a loading control. Patterns are
representative of those obtained in three independent experiments (left panel).
The amounts of caveolin-1 and Cav-1-pY14 present in each sample were
determined by densitometry, normalized respect to β-tubulin respectively, and
expressed as a percentage of control (right panel). Data are the means ± S.D. of
three different experiments, *, p < 0.01 versus controls, cells treated with
vehicle only.
Effects of PDMP treatment on caveolin-1 expression and caveolin-1
phosphorylation level
In order to demonstrate that pY14 Cav-1 takes part in gangliosides regulation of A2780
cell motility and adhesion, A2780/SAT-I 4T cells were treated with L- or D-PDMP for
24 hours or 48 hours. After the treatment, cells were lysed and analyzed by Western
blotting with specific antibodies against caveolin-1 and pY14 Cav-1. As shown in
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Figure 20, both L- and D-PDMP treatment had no effect on caveolin-1 expression.
However, D-PDMP, but not L-PDMP treatment was able to reduce caveolin-1
phosphorylation levels in A2780/SAT-I cells in a time dependent manner. Thus, in
A2780 cell model, the phosphorylation level of caveolin-1 is related to gangliosides
patterns, further indicating that gangliosides modulation of A2780 cells through
caveolin-1 phosphorylation.
Figure 20. Effects of PDMP treatment on caveolin-1 expression and
caveolin-1 phosphorylation level. A2780/SAT-I 4T cells were treated with 20
μM L- or D-PDMP for 24 and 48 hours. Total cell lysate from control or
PDMP treatment cells were analyzed by Western blotting detection using
specific antibodies against caveolin-1 and Cav-1-pY14. β-tubulin was
simultaneously detected as a loading control. Patterns are representative of
those obtained in three independent experiments (lower panel). The amount of
caveolin-1 and Cav-1-pY14 present in each sample were determined by
densitometry, normalized respect to β-tubulin respectively, and expressed as a
percentage of time-matched controls (upper panel). Data are the means ± S.D.
of three independent experiments. *, p < 0.01 versus controls, cells treated with
vehicle only.
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The data reported in this thesis and our previously published results (4,5), indicate that,
in human ovarian cancer cells, an increase in cellular gangliosides content, caused by
the overexpression of GM3 synthase, is paralleled by a marked up-regulation of the
membrane protein adaptor caveolin-1. The result of these concomitantly high levels of
gangliosides and caveolin-1 is a marked reduction of in vitro cell motility and an
increase of adhesion.
Genetic manipulation of GM3 synthase levels by its stable overexpression in the case of
SAT-I transfected cells, or the selective pressure in the presence of a drug (N-(4-
hydroxyl)retinamide) in the case of A2780/HPR cells, allowed to obtain two cellular
models in which higher GM3 synthase activity, compared with wild type cells,
determined an up-regulation of caveolin-1, a reduced cell motility, and an increased cell
adhesion. The existence of a causal connection between high levels of gangliosides and
the observed reduction of cell motility/increased adhesive ability is supported by
experiments in which exogenous gangliosides were administered to wild type cells, and
also by depletion experiments, in which the ganglioside content was markedly reduced
upon usage of the glucosylceramide synthase inhibitor, D-PDMP. The pharmacological
inhibition of glucosylceramide synthase led to a strong enhancement of cell motility and
a reduction of the cell adhesion. High ganglioside levels, therefore, are necessary, but
not sufficient, to up-regulate cell adhesion and, in turn, down-regulate cell motility.
Moreover it has been shown that cells with a higher activity of GM3 synthase, also have
a higher expression of caveolin-1, and the silencing of this protein led to an altered cell
adhesion. Thus, the regulation of cell adhesion requires a certain degree of cooperation
between gangliosides and caveolin-1. Caveolin-1, a hydrophobic membrane protein,
was originally described as the main structural component of caveolae, omega-shaped
invaginations of the plasma membrane that form a subdomain of cholesterol- and
sphingolipid-rich lipid rafts and that are morphologically distinct from the triskelion
structure of clathrin-coated pits (95). Soon though this protein gained a role as a
molecular organizer for multiprotein signaling complexes, due to its ability to interact
with several proteins involved in signal transduction through its scaffolding domain,
and to concentrate whole signaling modules in specialized plasma membrane areas,
allowing their functional regulation. Caveolin-1 is insoluble in cold non-ionic detergents
(237), and can be enriched in low density, Triton X-100-insoluble membrane fractions.
These fractions, which are also highly enriched in cholesterol and sphingolipids,
putatively correspond to lipid rafts. Thus, caveolin-1 at the plasma membrane is
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concentrated in a lipid-rich membrane environment, and lipids affect several of the
functionally relevant properties of caveolin-1. Caveolin-1 and sphingolipids not only
co-localize in the same detergent-resistant membrane fraction, but several pieces of
evidence indicate that they can be close enough in specialized membrane subdomains to
allow a direct interaction between the transmembrane domain of caveolin-1 and the
hydrophobic moiety of the lipids (227,238). In SAT-I transfected A2780 ovarian
carcinoma cells, photoreactive GM3 is able to label caveolin-1 in a detergent resistant
membrane preparation (4). In a few cases, it has been also reported that detergent-
resistant association of caveolin-1 and sphingolipids is strong enough to allow co-
immunoprecipitation. In CHO cells transiently transfected by GD3 synthase cDNA,
caveolin-1 can be immunoprepitated by a monoclonal antibody to ganglioside GD3
(239).
It has been reported that caveolin-1 and gangliosides are enriched in a Triton X-100
insoluble fraction and that a significant portion of the sphingolipids associated with the
DRM fraction can be recovered upon immunoprecipitation with anti-caveolin-1
antibody (5). It has therefore been hypothesized that the formation of a
ganglioside/caveolin-1 complex, occurring in cells with concomitantly high levels of
both components, might be involved in the negative regulation of ovarian carcinoma
cell motility. Several pieces of evidence indicate that integrin receptor subunits and the
non-receptor tyrosine kinase c-Src are enriched together with caveolin-1 and
sphingolipids within detergent-resistant membrane fractions. Moreover, integrin
receptor subunints and c-Src co-immunoprecipitate with caveolin-1 as shown in figure
16 and 17. Caveolin-1 (6,7) and c-Src (240,241) are typically associated with
sphingolipid-enriched membrane domains. In addition, in has been suggested that
caveolin-1 might act as a membrane adapter, coupling integrin receptor to Src kinases
(191) and that caveolin-1 mediated inactivation of the integrin/Src/FAK pathway might
be responsible for the inhibition of metastatic potential in melanoma (242). Previously
published data from our group strongly support the hypothesis that the inactivation of c-
Src by ganglioside/caveolin-1 complex might result in the downregulation of ovarian
carcinoma cell motility. We have previously shown that a Src inhibitor was able to
inhibit the motility of A2780 wild type cells, which express low GM3 synthase and low
caveolin-1, and that c-Src was less active in SAT-I transfected cells, expressing high
caveolin-1 levels (4).
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Moreover, we noticed that reducing the ganglioside content by D-PDMP treatment did
not influence the expression of caveolin-1, c-Src and integrin, but altered the
distribution of these molecules. As shown in figure 15, Caveolin-1 moved from the
DRM fraction to the intermediate fraction, whose composition and biological function
are still unclear. c-Src showed a distribution pattern similar to caveolin-1. Integrin α5
and integrin β1, shifted from the high density fraction to both DRM and intermediate
fractions. These results imply that the change in the ganglioside composition resulted in
the shift of molecules related to ganglioside signaling. It has also been shown that D-
PDMP treatment can also reduce caveolin-1 motility, thus we supposed that caveolin-1
may bind to other molecules in the case of D-PDMP treatment. Since caveolin-1 and
both integrin α5 and integrin β1 tend to move to the intermediate fraction after
ganglioside depletion, integrin α5 and integrin β1 are possible candidates to associate
with caveolin-1, thus slowing down caveolin-1 motility after D-PDMP treatment.
Immunoprecipitation experiments with a polyclonal anti-caveolin-1 antibody supported
this hypothesis showing an increase of both integrin α5 and integrin β1 associated with
the caveolin-1 immunoprecipitate. In the case of integrin β1, the increase is referred to
its mature fully glycosylated form, suggesting that this form is the one that interacts
with caveolin-1 and takes part in the formation of the signaling complex.
Investigating in vitro cell adhesion to different extracellular matrix proteins, allowed us
to hypothesize the presence of other integrin subunits involved in the regulation of the
adhesion of A2780 ovarian carcinoma cells. The adhesion of both A2780 wild type and
SAT-I transfected cells, not only to fibronectin which bind to integrin α5β1, the major
integrin type expressed in these cells, but also to laminin and vitronectin suggest that
integrin subunints such as αVβ1 and αVβ5, which bind vitronectin, or α3β1 and α6β1,
which bind laminin, may have a role in regulating adhesion and motility, maybe by
participating to the organization of a signaling complex involving caveolin-1.
Vitronectin though also competes with fibronectin for its binding to α5β1, and it has
been shown that Src family tyrosine kinases are required for fibronectin receptor α5β1
and vitronectin receptor αVβ5-mediated cell adhesion (243). Taken together, all these
data suggest a novel role of gangliosides in the regulation of cell motility and adhesion
in human ovarian carcinoma cells, by affecting the organization of a signaling complex
organized by caveolin-1 and integrin α5, responsible for c-Src inactivation.
Our results call the attention to other aspects that probably deserve future consideration.
First, despite the much higher expression of caveolin-1, the morphological analysis
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revealed the absence of caveolae both in A2780/HPR and A2780/SAT-I transfected
cells, as in the wild type A2780 cells. This finding might seem in contrast with the usual
association between caveolin-1 and caveolae, but it is indeed in agreement with the
diverse and multiple caveolae-independent roles of caveolin-1 that have been described
in the last few years (6,7,244). The second aspect is related to the observation that
cellular ganglioside or GM3 synthase levels can regulate the expression of caveolin-1. It
has been shown that GD1a ganglioside regulated caveolin-1 expression in FBJ mouse
osteosarcoma cells (245). Also in that case, the concomitant increase in certain
gangliosides and in caveolin-1 seems to be related to the possible role of caveolin-1 as a
tumor suppressor. FBJ mouse osteosarcoma cells and A2780 human ovarian carcinoma
cells exist in different phenotypic variants, characterized by strikingly different in vitro
cell motility. For both cell types, the low motility variants are characterized by high
ganglioside and low caveolin-1 expression, while the high motility variants contain low
ganglioside and low caveolin-1 levels. Treatment of high motile FBJ-LL osteosarcoma
cell line with exogenous GD1a upregulation of caveolin-1 expression with reduced
metastatic potential and suppressed cell adhesion to vitronectin (246). Similarly, GM3
synthase-transfected A2780 ovarian carcinoma cells were characterized by an increased
expression of caveolin-1 and reduced in vitro cell motility. These cells also show a
markedly increased in vitro cell adhesion to fibronectin, whereas the increase in their
adhesion to laminin and vitronectin is not so striking. However, the mechanism
underlying the regulation of caveolin-1 expression by the cellular gangliosides levels is
totally unknown. The relationship between ganglioside and other molecules related to
this signaling pathway needs to be further investigated.
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